
Title: An Open-Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With 
Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That 
Has Progressed During or After Aromatase Inhibitor Therapy
MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer 
After Aromatase Inhibitor Therapy
Study ID: [REMOVED]
Protocol Approve Date: 02 October 2017
Certain information  within this protocol has been  redacted (ie,  specific content is masked irreversibly from view 
with a black/blue  bar) 
to protect either personally identifiable information (PPD) or company confidential 
information (CCI)
. 
This may include, but is not limited to, redaction of the following: 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal  information, or 
to otherwise protect the integrity of the clinical study.
PROTOCOL
An Open -Label Phase 2 Study of MLN0128 (A TORC1/2 Inhibitor) in Combination With 
Fulvestrant in Women With ER -Positive/HER2- Negative Advanced or Metastatic Breast 
Cancer That Has Progressed During or Af ter Aromatase Inhibitor Therapy
MLN0128 in Combination With Fulvestrant in Women With Advanced or Metastatic 
Breast Cancer After Aromatase Inhibitor Therapy
Sponsor: Millennium Pharmaceut icals, Inc., a wholly owned subsidiary of Takeda 
Pharmaceut ical Co mpany Limited
40 Landsdowne Street
Cambridge, MA02139 USA
Telephone: +1 (617) 679 -7000
Please note: Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda 
Pharmaceutical Company Limited, may be referred to in t his protocol as 
“Millennium”, “s ponsor”, or “Takeda”.
Study Number: C31006
IND Number: 126,346 EudraCT Number: 2015-003612-20
Compound: MLN0128 (TAK -
228)
Date: 02 October 2017 Amendment Number: 3
Amendment History :
Date Amendment NumberAmendment Type (for regional 
Europe purposes only) Region
10 February 2016 Initial Proto col Not applicable Global
30 March 2016 1 Nonsubstantial Global
07 March 2017 2 Substantial Global
02 October 2017 3 Substantial Global
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 2of 105
Protocol Incorporating Amendment No. 3 02 October 2017
1.0 ADMINISTRATIVE
1.1 Contacts
A separate contact informat ion list will be provided to each site.
Serious adverse event (SAE) reporting information is presented in Sect ion 11.0, as i s informat ion 
on reporting product complaints.
Takeda Development Cente r, Inc. (TDC) sponsored invest igators, per individual country 
requi rements, will be provided with emergency medical contact informat ion cards to be carried by 
each subject.
General advice on protocol procedures should be obtained through the monitor assign ed to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role North America Europe
SAE reporting See Section 11.2 See Section 11.2
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 3 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
1.2 Approval
REPRESENTATIVES OF TAKEDAThis study will be conducted with the highest respect for the individual participants in accordance 
with the requirements of this clinical study protoc ol and also in accordance with the following:
!The ethical principles that have their origin in the Declaration of Helsinki.
!International Conference on Harmonisation E6 Good Clinical Practice: Consolidated 
Guideline.
!All applicable laws and regulations, including, without limitation, data privacy laws, clinical 
trial disclosure laws, and regulations.
SIGNATURES
The signature of the responsible medical officer (and other signatories, as applicable) can be found 
on the signature page.
Electronic Signatures may be found on the last page of this document.
PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usedance ance
wing:wing:
olidatedlidate
a privacpriva
natories,atorie
thihis docs do
nd Subje
da: For Non-Commercial Use Only and
MLN0128 (TAK -228)
Study No. C31006 Page 4of 105
Protocol Incorporating Amendment No. 3 02 October 2017
INVESTIGATOR AGREEMENT
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, 
fulvestrant package insert, and any  other product informat ion provi ded by  the sponsor. I agree to 
conduct thi s study  in accordance wit h the requirements of this protocol and also to protect the 
rights, safet y, privacy, and well -being of study  subjects in accordance wit h the fo llowing:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference o n Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting SAEs defined in Section 11.0 of this protocol .
Terms outlined in the Clinical Study  Site Agreement.
Appendix B–Responsibilit ies o f the Invest igator.
I further authorize that my  personal informat ion may be processed and transf erred in accordance 
with the uses contem plated in
 Appendix Cof this protocol .
Signature of Investigator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Prov ince)
Locati on of  Facilit y (Country )
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 5of 105
Protocol Incorporating Amendment No. 3 02 October 2017
1.3 Protocol Amendment 3 Summary of Changes
Rationale for Amendment 3
This document describes the changes in referenc e to the protocol incorporating 
Amendment No.03. The primary reason for this amendment is to update those secti ons affected 
by new nonclinical data for MLN0128 metabo lism by specific cytochrome P450 (CYP) iso forms. 
The study ’s exclusion criteria, list of pro hibited conco mitant m edicat ions, list of relevant CYP
inhibitors and inducers, and dietary  restri ctions related to CYP inhibitors and inducers have been 
updated accordingly . The number of study  sites, r ecommendat ions for init iation of crossover 
treatm ent,and guidance for fast ing serum glucose post -dose collect ion have also been updated . 
Minor gramma tical, editorial, and formatting changes are included for clarificat ion purposes only.
For specific descript ions of text changes and where the changes are located, see Appendix J.
Changes in Amendment 03
1.Remove the exclusio n criterion relating to treatment with strong CYP inhibitors or inducers.
2.Update the list of concomitant medicat ions prohibited during the study.
3.Update the list of relevant CYP inhibitors and inducers.
4.Remove di etary  restri ctions rel ated to CYP i nhibit ors and inducers.
5.Update thenumber of study  sites.
6.Update the recommendations for init iation of crossover treatment.
7.Update gui dance for fasting serum glucose post-dose collect ion on non
-dosing days.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 6of 105
Protocol Incorporating Amendment No. 3 02 October 2017
TABLE OF CONTENTS
1.0 ADMINISTRATIVE ....................................................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Amendment 3 Summary  of Changes ............................................................ 5
2.0 STUDY SUMMARY .................................................................................................... 12
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 15
3.1 Study -Related Responsibilit ies................................................................................. 15
3.2 Principal Invest igator/Coordinating Invest igator ...................................................... 15
3.3 List of Abbreviat ions............................................................................................... 16
3.4 Corporate Identificat ion........................................................................................... 18
4.0 INTRODUCTION ......................................................................................................... 19
4.1 Background ............................................................................................................. 19
4.1.1 Disease Under Treatm ent: Breast Cancer ....................................................... 19
4.1.2 Study  Drug: MLN012 8.................................................................................. 20
4.1.3 Nonclinical Experience .................................................................................. 20
4.1.3.1 Clinical Experience with MLN0128 ............................................................. 20
4.1.3.2 Preliminary Data in Wo men With ER -Positive/HER2- Negative Breast 
Cancer Wit h MLN0128 in Co mbinat ion Wit h Exemestane or Fulvestrant ....21
4.1.3.3 Risk-Benefi t Assessment for th e Use of MLN0128 in 
ER-Positive/HER2- Negative Breast Cancer .................................................. 22
4.2 Rationale for the Proposed Study ............................................................................. 22
5.0 STUDY OBJECTIVES .................................................................................................26
5.1 Primary Object ives.................................................................................................. 26
5.2 Secondary  Object ives............................................................................................... 26
5.3 Health-Relat ed Qualit y of Life Object ive.................................................................26
5.4 Exploratory  Objectives ............................................................................................ 26
6.0 STUDY ENDPOINTS ................................................................................................... 28
6.1 Primary Endpo int..................................................................................................... 28
6.2 Secondary  Endpo ints............................................................................................... 28
6.3 Health-Related Qualit y of Life Endpo ints................................................................ 28
6.4 Exploratory  Endpo ints............................................................................................. 28
7.0 STUDY DESIGN .......................................................................................................... 29
7.1 Overview of Study  Design ....................................................................................... 29
7.1.1 Enrollment and Rando mizat ion..................................................................... 29
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 7of 105
Protocol Incorporating Amendment No. 3 02 October 2017
7.1.2 Weekly MLN0128 Dose Confirmat ion (Arm C) ............................................ 30
7.1.3 Study  Evaluat ions (All Treatment Arms) ....................................................... 31
7.1.4 Potenti al for Crossover Treatm ent.................................................................31
7.1.5 Potenti al for Single -Agent MLN0128 Dosing ................................................ 32
7.2 Number of Patients .................................................................................................. 32
7.3 Durati on of  Study .................................................................................................... 32
8.0 STUDY POPULATION ................................................................................................ 34
8.1 Inclusio n Cri teria..................................................................................................... 34
8.2 Exclusio n Cri teria.................................................................................................... 35
9.0 STUDY DRUG ............................................................................................................. 38
9.1 Study  Drug Administration: Fulvestrant Plus MLN0128 .......................................... 38
9.2 Reference/Control Ther apy: Single -Agent Fulvestrant ............................................. 39
9.3 Definit ions of DLT (Weekly MLN0128 Dose Confirmat ion)................................... 39
9.4 Dose Modificat ion Guidelines .................................................................................. 40
9.4.1 MLN0128 Dose Interruption ......................................................................... 40
9.4.2 MLN0128 Dose Reduction ............................................................................ 41
9.4.3 Discontinuati on of  MLN0128 ........................................................................ 41
9.5 Excluded Conco mitant Medi cations and Procedures ................................................ 41
9.5.1 Excluded Conco mitant Medi cations and Procedures for Single -Agent 
Fulvestrant Treatment Arm (Arm A) ............................................................. 41
9.5.2 Excluded Conco mitant Medi cations and Procedures for Combinat ion 
MLN0128 Plus Fulvestrant Treatment Arms (Arm B and Arm C)................. 42
9.6 Permi tted Concomitant Medications and Procedures (All Treat ment Arm s)............. 42
9.7 Precauti ons and Restri ctions.................................................................................... 43
9.8 Management of Clinical Events ............................................................................... 43
9.8.1 Management of Hyperglycemia ..................................................................... 43
9.8.2 Management of Hyperlipidemia .................................................................... 45
9.8.3 Management of Oral Mucosit is...................................................................... 46
9.8.4 Management of Rash ..................................................................................... 47
9.8.5 Management of Nausea and/or Vomit ing....................................................... 48
9.8.6 Management of Noninfectious Pneumo nitis................................................... 49
9.8.7 Management of Other Nonhematologic Toxicit ies......................................... 50
9.9 Blinding and Unblinding ................................
.......................................................... 50
9.10 Descript ion of Invest igational Agents ...................................................................... 50
9.11 Preparati on, Reconstitution, and Dispensat ion.......................................................... 50
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 8of 105
Protocol Incorporating Amendment No. 3 02 October 2017
9.12 Packaging and Labeling ........................................................................................... 51
9.13 Storage, Handling, and Accountabilit y..................................................................... 51
10.0 STUDY CONDUCT ...................................................................................................... 53
10.1 Study  Personnel and Organizations .......................................................................... 53
10.2 Arrangements for Recruit ment of Patients ................................................................ 53
10.3 Treatment Group Assignments ................................................................................. 53
10.4 Study  Procedures ..................................................................................................... 54
10.4.1 Inform ed Consent .......................................................................................... 54
10.4.2 Patient Dem ographi cs.................................................................................... 54
10.4.3 Medical History ............................................................................................. 54
10.4.4 Enrollment .................................................................................................... 54
10.4.5 Patient Hei ght and Weight ............................................................................. 55
10.4.6 Physical Examinat ion.................................................................................... 55
10.4.7 Vital Signs..................................................................................................... 55
10.4.8 ECOG Performance Stat us............................................................................ 55
10.4.9 ECG .............................................................................................................. 55
10.4.10 Disease Assessment ....................................................................................... 55
10.4.10.1 CT Scan or MRI ..................................................................................... 55
10.4.10.2 Bone Scan .............................................................................................. 56
10.4.10.3 Health-related Qualit y of Life Assessments ............................................ 56
10.4.11 Concomitant Medications and Procedures ..................................................... 56
10.4.12 AEs ............................................................................................................... 56
10.4.13 Patient Diary Instructi on and Revi ew............................................................. 57
10.4.14 Clinical Laboratory  Evaluat ions.................................................................... 57
10.4.15 In-Hom e Daily FBG Monitoring (Combinat ion Arms Only) .......................... 58
10.4.16 Biomarker Measurem ents in Bl ood................................................................ 59
10.4.17 Circulat ing Tumor Cells ................................................................................ 59
10.4.1 8Banked Tum or Specimen Measurements ....................................................... 59
10.4.19 PK Measurements (Combinat ion Arms Only) ................................................ 60
10.5 Com pletion of Study  Treatm ent............................................................................... 60
10.6 Com pletion of Study ................................................................................................ 60
10.7 Discontinuati on of  Treatment Wi th Study  Drug ....................................................... 60
10.8 Withdrawal o f Patients From  Study ......................................................................... 61
10.9 Study  Com pliance .................................................................................................... 61
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 9of 105
Protocol Incorporating Amendment No. 3 02 October 2017
10.10 Post-Treatment Follow -up Assessments (Progre ssion -Free Survival and Overall 
Survival) .................................................................................................................. 61
11.0 ADVERSE EVENTS .................................................................................................... 63
11.1 Definit ions............................................................................................................... 63
11.1.1 PTE Definit ion.............................................................................................. 63
11.1.2 AE Definit ion................................................................................................ 63
11.1.3 SAE Definit ion.............................................................................................. 63
11.2 Procedures for Recording and Reporting AEs and SAEs .......................................... 64
11.3 Moni toring of AEs and Period of Observat ion......................................................... 65
11.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events ......... 66
11.5 Procedures for Reporting Product Complaints .......................................................... 66
11.6 Safety Reporting to Invest igators, IRBs or IECs, and Regulatory  Authori ties........... 66
12.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 67
13.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 68
13.1 Electronic Case Report Forms .................................................................................. 68
13.2 Record Retention ..................................................................................................... 68
14.0 STATISTICAL METHODS .......................................................................................... 70
14.1 Statistical and Analyt ical Plans ................................................................................ 70
14.1.1 Analysis Sets .................................................................................................70
14.1.2 Analysis of Demographics and Other Baseline Characterist ics...................... 70
14.1.3 Efficacy Analysis .......................................................................................... 70
14.1.3.1 Primary Efficacy  Endpoint ..................................................................... 70
14.1.3.2 Secondary  Efficacy  Endpoints ................................................................ 70
14.1.4 PK Analysis .................................................................................................. 71
14.1.5 Pharmacodynamic Analyses/Bio marker Analyses .......................................... 71
14.1.6 Patient-Reported Outcomes ........................................................................... 71
14.1.7 Safety Analysis .............................................................................................. 72
14.2 Interim Analysis and Criteria for Early Terminat ion................................................ 73
14.3 Determinat ion of Sample Size .................................................................................. 73
15.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 74
15.1 Study -Site Moni toring Visit s................................................................................... 74
15.2 Protocol  Deviat ions.................................................................................................. 74
15.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 74
16.0 ETHICAL ASPECTS OF T HE STUDY ................................ ........................................ 75
16.1 IRB and/or IEC Approval ........................................................................................ 75
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 10of 105
Protocol Incorporating Amendment No. 3 02 October 2017
16.2 Subject Informat ion, Inform ed Consent, and Subject Authori zation......................... 76
16.3 Subject Confidentialit y............................................................................................ 77
16.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................77
16.4.1 Publicat ion and Disclosure ............................................................................ 77
16.4.2 Clinical Trial Registration ............................................................................. 78
16.4.3 Clinical Trial Result s Disclosure ................................................................... 78
16.5 Insurance and Co mpensation for Injury .................................................................... 78
17.0 REFERENCES .............................................................................................................. 79
LIST OF IN -TEXT TABLES
Table 4.a DLT Observed Wit h Weekly  MLN0128 in Study MLN0128 -1004 .................... 24
Table 9.a Examples of a Light Meal .................................................................................. 38
Table 9.b Dose Reductions for MLN0128 .......................................................................... 41
Table 9.c Management of Hyperglycemia ......................................................................... 45
Table 9.d Management of Hyperlipidemia ......................................................................... 46
Table 9.e Management of Oral Mucosit is.......................................................................... 47
Table 9.f Management of Rash ......................................................................................... 48
Table 9.g Management of Nausea and/or Vomit ing........................................................... 49
Table 9.h Management of Noninfectious Pneumo nitis....................................................... 49
Table 9.i Management of Asthenia, Weakness, and Fatigue .............................................. 50
Table 10.a Clinical Chemistry , Hem atology, and Coagul ation Tests .................................... 57
Table 10.b Clinical Urinalysis Tests .................................................................................... 57
Table 10.c Fasting Lipid Profile .......................................................................................... 58
LIST OF IN -TEXT FIGURES
Figure 7.a C31006 Study  Design ........................................................................................ 30
LIST OF APPENDICES
Appendix A Schedule of Events ............................................................................................. 83
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 91
Appendix C Invest igator Consent to Use of Personal Informat ion.......................................... 93
Appendix DECOG Scal e for Perf ormance Status .................................................................. 94
Appendix ECockcroft -Gaul t Equati on.................................................................................. 95
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 11of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix FNew York Heart Associat ion Classi fication of Cardi ac Disease .......................... 96
Appendix G List of Relevant Cy tochrom e P450 Inhibitors and Inducers ................................ 97
Appendix H EORTC QLQ -C30 Ver sion 3 ............................................................................. 98
Appendix I EORTC QLQ -BR23 ......................................................................................... 100
Appendix J Detailed Descript ion of Amendments to Text ................................................... 102
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 12 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
2.0 STUDY SUMMARY 
Name of Sponsor(s):
Millennium Pharmaceuticals, Inc.Compound:
MLN0128 (TAK-228)
Title of Protocol: An Open-Label Phase 2 Study of 
MLN0128 (A TORC1/2 Inhibitor) in Combination With Fulvestrant in Women With ER-Positive/HER2-Negative Advanced or Metastatic Breast Cancer That Has Progressed 
During or After Aromatase Inhibitor Therapy.IND No.: 126,346 EudraCT No.: 
2015-003612-20
Study Number: C31006 Phase: 2
Study Design:
This phase 2, open-label, randomized, 3-arm study is designed to evaluate the efficacy and safety of the combination 
of fulvestrant+daily MLN0128 compared with single-agent fulvestrant, and the combination of fulvestrant+weekly (QW) MLN0128 compared with single-agent fulvestrant in the treatment of postmenopausal women with advanced or metastatic estrogen receptor (ER) positive, human epidermal growth factor receptor-2 (HER2) negative breast cancer that has progressed during or after aromatase inhibitor (AI) therapy. Patients who meet all eligibility criteria will be stratified according to the presence or absence of visceral metastasis (defined as all lesions not included in the following list: breast, skin, subcutaneous tissue, lymph node or bone), previous sensitivity to hormonal therapy, and 
previous exposure to cyclin-dependent kinase (CDK) 4/6 inhibitors and will be randomized 1:1:1 to 1 of 3 treatment 
arms: 
!Arm A: Single-agent fulvestrant.
!Arm B: Combination of fulvestrant+daily MLN0128.
!Arm C: Combination of fulvestrant+weekly MLN0128.
A safety and tolerability assessment will be performed for the first 6 evaluable patients in Arm C treated with 
fulvestrant+30 mg weekly MLN0128. After the sixth evaluable patient completes Cycle 1, a review will be performed: if ≤1 dose-limiting toxicity (DLT; see Section  9.3) occurs, the MLN0128 dose for this treatment arm will 
remain the same (ie, 30 mg weekly MLN0128, in combination with fulvestrant); if ≥2 DLTs occur, all patients 
subsequently randomized to this tr eatment arm will receive a starting dose of 20 mg weekly MLN0128 in combination 
with fulvestrant. For any patients initially assigned to the 30 mg weekly starting dose, the MLN0128 dose may be 
decreased if necessary per the dose modification criteria in Section  9.4.
Safety assessments (including adverse events [AEs], serious adverse events, laboratory assessments, vital signs, 
electrocardiograms, Eastern Cooperative Oncology Group [ECOG] performance status, and weight) will be performed throughout the treatment period, including the End-of-Treatment (EOT) visit, to evaluate the safety and tolerability of MLN0128. Radiological tumor evaluations will be used to evaluate disease response according to 
Response Evaluation Criteria in Solid Tumors (RECIST) guidelines (Version 1.1) [1].
 
 
 
 
 
Patients will receive study medication(s) until disease progression (progressive disease [PD]), unacceptable toxicity, 
or withdrawal of consent. Patients who discontinue study treatment for reasons other than PD will continue to have progression-free survival (PFS) follow-up visits every 2 months for the first 6 months after the EOT Visit and then 
every 3 months, until PD or start of another anticancer therapy, whichever occurs first. After PD or start of another 
anticancer therapy, patients will be followed for survival every 6 months.
Patients in the single-agent fulvestrant arm who have confirmed PD may be allowed to receive crossover treatment 
with fulvestrant+MLN0128. CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Appliand safetysafe
bination oinatio
enopausanopaus
eptorptor--2 (H2
s wwho meho mwwww
ined as ned as al
previousprevious
and will and wil
N0128.128.
med for tmed fo
sixth evasixth ev
; see Sec; see S
0128, in c28, in
ent arm warm
tially assally a
se modifie modi
adverse dvers
n CooperCoopplicable Terms of Useofof
0s
ca
he treatme treatm
128. Rad28. Ra
on Criteron Crit
PatienPatie
orowpli
pepea: Feda:ked
Takeof Tayo f  
MLN0128 (TAK -228)
Study No. C31006 Page 13of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Primary Objectives:
To compare the PFS of patients treated with the combination of fulvestrant+daily MLN0128 versus patients 
treated with single -agent fulvestrant.
To compare the PFS of patients treated with the combination of fulvestrant+weekly MLN0128 versus patients 
treated with single -agent fulvestrant.
Secondary Objectives:
To compare secondary effi cacy endpoints in patients treated with the combination of fulvestrant+daily MLN0128 
versus patients treated with single -agent fulvestrant.
To compare secondary efficacy endpoints in patients treated with the combination of fulvestrant+weekly 
MLN0128 versu s patients treated with single -agent fulvestrant.
To assess the safety and tolerability of the combination of fulvestrant+MLN0128.
To collect plasma concentration -time data with sparse pharmacokinetic (PK) sampling (combination 
fulvestrant+MLN0128 treatment arms [Arm B and Arm C] only) to contribute to future population PK analysis.
Subject Population: Postmenopausal women with advanced or metastatic ER -positive/HER2 -negative breast cancer 
that has progressed during or after AI therapy. Enrollment will be managed to ensure that approximately 40% of 
enrolled patients have previously received a CDK4/6 inhibitor in combination with an AI.
Number of Subjects: Approximately 153 patients (51 per 
treatment arm).Number of Sites: Approximately 65study centers in 
the United States and Europe.
Dose Level(s):
Arm A, single -agent fulvestrant: fulvestrant, 500 mg 
intramuscularly (IM), on Cycle 1 Days 1 and 15 
(loading regimen), and then on Day 1 of each 
subsequent 28 -day treatment cycle.
Arm B, combination of fulvestr ant+daily MLN0128: 
fulvestrant as above plus MLN0128, 4 mg orally (PO) 
every day (QD) of a 28 -day treatment cycle.
Arm C, combination of fulvestrant+weekly MLN0128: 
fulvestrant as above plus MLN0128, 30 mg PO QW of 
a 28-day treatment cycle.Route of Admini stration:
Fulvestrant: IM.
MLN0128: PO.
Duration of Treatment:
Patients will receive study medication(s) until PD, 
unacceptable toxicity, or withdrawal of consent.Period of Evaluation:
Patients who discontinue study treatment for reasons 
other than PD wi ll continue to have PFS follow -up 
visits ever y 2 months for the first 6 months after the 
EOT Visit, and then ever y 3 months until PD or start of 
another anticancer therapy (whichever occurs first). 
After PD or start of another anticancer therapy, patients 
will be followed for survival ever y 6 mo nths. 
Main Criteria for Inclusion:
Postmenopausal women with local histological confirmation of ER -positive/HER2 -negative metastatic or advanced 
breast cancer; measurable extra -osseous lesion, or measurable bone le sion (lytic or mixed); ECOG status of 0 or 1; PD 
during or after prior AI therapy, defined as recurrence during or within 12 months after discontinuation of adjuvant 
therapy  or defined as PD during or within 1 month after discontinuation in the metastatic setting; adequate bone 
marrow, coagulation, hepatic, cardiac, renal, and metabolic function.
Main Criteria for Exclusion:
Prior therapy  with mechanistic target of rapamycin (mTOR) inhibitors, phosphoinositide -3-kinase (PI3K) inhibitors, 
dual PI3K -mTOR inh ibitors, serine/threonine -specific protein kinase (AKT; also known as protein kinase B) 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 14of 105
Protocol Incorporating Amendment No. 3 02 October 2017
inhibito rs, or fulvestrant; prior treatment with >1 line of chemotherapy for metastatic breast cancer; experienced PD 
on >2 endocrine therapies for metastatic breast ca ncer; significant previous or existing cardiac conditions; other 
comorbidities of interest (including poorly controlled diabetes mellitus, significant pulmonary disease).
Main Criteria for Evaluation and Analyses:
The primary endpoint for this study is PF S. Secondary endpoints for this study are overall survival (OS), time to 
progression (TTP), objective response rate (ORR), clinical benefit rate (CBR) with stable disease (SD) of any 
duration, CBR with SD duration of at least 6 months, and the number and p ercentage of patients with 
treatment -emergent AEs.
Statistical Considerations:
The primary endpoint, PFS, is defined as the time from the date of randomization to the date of first documentation of 
progression or death due to any cause, whichever occurs f irst. For a patient whose disease has not progressed and is 
last known to be alive, or started alternate therapy prior to PD, PFS will be censored at the last response assessment 
that is SD or better. The Kaplan -Meier method will be used to analyze the dis tribution of PFS for each treatment arm. 
The primary hypothesis is to be tested at the 0.10 significance level (2 -sided). The p -values from a stratified log -rank 
test and hazard ratios (HRs) will be presented for each pair -wise comparison.
Secondary effica cy endpoints include OS, ORR, TTP, CBR with SD of any duration, and CBR with SD duration of at 
least 6 months. OS is defined as the time from the date of randomization to the date of death. Patients without 
documentation of death at the time of analysis wi ll be censored at the date last known to be alive. OS will be analyzed 
using similar methods as the primary endpoint of PFS.
ORR is defined as the proportion of patients who achieve a best response of complete response (CR) or partial 
response (PR) according to RECIST 1.1 criteria [1]. CBR is defined as the proportion of patients who achieve a best 
response of CR, PR, or SD. The CBR will also be presented for a best response of CR, PR, and SD of at least 6 months. 
A stratified Cochran -Mantel -Haenszel test will be used to compare O RR and CBR between treatment arms. The 
Mantel -Haenszel estimate of the odds ratio and the associated 95% confidence intervals (CIs) will be presented for 
each pair -wise comparison.
TTP is defined as the time from the date of randomization to the date of fi rst documentation of progression. For a 
patient whose disease has not progressed, TTP will be censored at the last response assessment that is SD or better. 
TTP will be analyzed using similar methods as the primary endpoint of PFS.
Sample Size Justificati on:Assuming that the median PFS is 4 months for single -agent fulvestrant and that the 
combinatio n of fulvestrant+MLN0128 (administered either QD or QW) can improve the median PFS to 8months (HR 
of 0.5), then a total of 72 PFS events are needed for each p air-wise comparison. Each treatment arm will require 
51patients (1:1:1 randomization allocation). The calculations are based on a power of 90%, 2 -sided alpha of 10%, and 
a dropout rate of 10% due to either lost to follow -up or withdrawal of consent.
The s ample size for the study assumes the accrual duration will be approximately 14 months. The final analysis for the 
pair-wise comparison of PFS between fulvestrant+daily MLN0128 and fulvestrant, and between fulvestrant+weekly 
MLN0128 and fulvestrant, is esti mated to occur approximately 20 months after the first patient is randomized. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 15of 105
Protocol Incorporating Amendment No. 3 02 October 2017
3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Clinical Study  Supplier List (or equivalent). 
3.2 Principal Investigator/Coordinating Investigator
The sponsor will select a Signatory  Coordinat ing Investigator from the invest igators who 
participate in the study . Selection criteria for thi s investi gator will include signific ant knowl edge 
of the study  protocol , the study  medication, thei r experti se in the therapeutic area and the conduct 
of clinical research as well as study participation. The Signatory Coordinat ing Invest igator will be 
requi red to revi ew and sign the clinical study  report and by doing so agrees that it accurately 
describes the results of the study .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 16of 105
Protocol Incorporating Amendment No. 3 02 October 2017
3.3 List of Abbreviations
AE adverse event
AI aromatase inhibitor
AKT serine/threonine -specific protein kinase (also known as protein kinase B)
ALP alkaline phosphat ase
ALT alanine aminotransferase
ANC absolute neutrophil count
ASCO American Society of Oncology 
AST aspartate aminotransferase
CAP College of American Pathologists 
CBR clinical benefit rate
CDK cyclin -dependent kinase 
CI confidence interval
CR complete response
CT computed tomography
CTC circulating tumor cell
ctDNA circulating tumor DNA
CYP cytochrome P450
DLT dose-limiting toxicity
DNA deoxyribonucleic acid
ECG electrocardiogram
ECOG Eastern Cooperative Oncology Group
eCRF electronic case report form
EORTC QLQ -C30 European Organization for Research and Treatment of Cancer QLQ Questionnaire, 
version 3.0
EORTC QLQ -BR23 European Organization for Research and Treatment of Cancer Breast Cancer -Specific 
Quality  of Life Questionnaire
EOT End-of-Treatment
ER estrogen receptor
FBG fasting blood glucose
FDA Food and Drug Administration
GCP Good Clinical Practice
GEICAM Grupo Español de Investigación en Cáncer de Mama
GI gastrointestinal
HDPE high-density polyethylene
HbA1c glycosylate d hemoglobin
HER2 human epidermal growth factor receptor -2 
Hgb hemoglobin
HR hazard ratio 
HRQL health -related quality of life
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 17of 105
Protocol Incorporating Amendment No. 3 02 October 2017
ICH International Conference on Harmonisation
IEC independent ethics committee
IM intramuscular; intramuscularly 
IRB institutional review board
IRT interactive response technology
IV intravenous; intravenously
MedDRA Medical Dictionary for Regulatory Activities
MLN0128 also known as TAK -228 and INK -128
MRI magnetic resonance imaging
mTOR mechanistic target of rapamyc in
NCI CTCAE Natio nal Cancer Institute Common Terminology Criteria for Adverse Events
ORR objective response rate
OS overall survival
PD progressive disease, disease progression
PFS progression -free survival
PgR progesterone receptor
PI3K phosphoino sitide -3-kinase
PIK3CA phosphoinositide -3-kinase, catalytic alpha polypeptide 
PK pharmacokinetic(s)
PO per os (orally administered)
PPI proton pump inhibitor
PR partial response
PRO patient -reported outcome
PTE pretreatment event
PTEN phosphatase and tensin homolog 
QD daily , once per day
QD x3 3 times, daily dosing
QD x5 5 times, daily dosing
QTc corrected QT interval
QW weekly, once per week
RECIST Response Evaluation Criteria in Solid Tumors
SAE serious adverse event
SAP statistical ana lysis plan
SD stable disease
SERD selective estrogen receptor downregulator
SERM selective estrogen receptor modulator
SmPC Summary of Product Characteristics
SUSAR suspected unexpected serious adverse reactions
TAK -228 also known as MLN0128
TEAE treatment -emergent adverse event
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 18of 105
Protocol Incorporating Amendment No. 3 02 October 2017
TORC1 target of rapamycin complex 1
TORC2 target of rapamycin complex 2
TTP time to progression
ULN upper limit of the normal range
US United States
USPI United States prescribing information
WHO World Health Organizat ion
3.4 Corporate Identification 
Millennium Millennium Pharmaceuticals, Inc, a wholly owned subsidiary of Takeda Pharmaceutical 
Company Limited.
TDC Europe Takeda Development Centre Europe Ltd.
TDC Americas Takeda Development Center Americas , Inc.
Takeda Millennium Pharmaceuticals, Inc, TDC Japan, TDC Asia, TDC Europe and/or TDC 
Americas, as applicable
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 19of 105
Protocol Incorporating Amendment No. 3 02 October 2017
4.0 INTRODUCTION
4.1 Background
4.1.1 Disease Under Treatment: Breast Cancer
Breast cancer is the most frequent cancer diagnosis in wo men and is the leading cause of 
cancer-related deaths in women in Europe and the second leading cause of cancer -related deaths in 
wom en in the United States. The American Cancer Society  estimates that approximately  232,340 
wom en in the US will receive a new diagnosis of breast cancer in 20 13 [2,3] . According to 
GLOBOCAN 2012, the incidence of breast cancer across Europe in 2012 was 458,718 
(http ://globocan.iarc.fr/pages/fact_sheets_populat ion.aspx, accessed 19 November 2015). 
Approximately  39,620 wom en in the United States and 131,347 women in Europe were predicted 
to die from their disease in 2013.
Breast cancer is a heterogeneous disease wit h different histologies, prognoses, natural history, 
responses to treatment, and molecular characteristics [
4-6]. Breast cancer can be classified into 
3major ca tegori es or subty pes: horm one receptor -positive tum ors that express estrogen receptor 
(ER), or progesterone receptors (PgRs), or both; tumors that over -express the receptor for human 
epidermal  growth factor receptor -2 (HER2); and basal epit helial -like or “ triple-negat ive tumors” 
that do not express hormone receptors or HER2 [
4,7]. Approximately 66% to 75% of br east 
cancers are hormone receptor -positive tumors [
4,6,8-10] .
Standard therapy  for ER -posit ive tumors in postmenopausal wo men, both in the adjuvant and 
metastati c disease settings, consists of single -agent ant iestrogen therapy . Ant iestrogen therapy for 
postm enopausal wom en wi th hormone receptor -posit ive breast cancer invo
lves the sequent ial use 
of selective ER modulators (SERMs; eg, tamoxifen), nonsteroidal or steroidal aromatase inhibitors 
(AIs) either as single agents or in combinat ions, and sel ective ER downregulators (SERDs; eg, 
fulvestrant) [10]. A combinat ion therapy  of the steroi dal AI letrozol e plus the cyclin -dependent 
kinase 4/6 (CDK4/6) inhibitor palbociclib is an addit ional treatment option for postmenopausal 
wom en as initial endocrine -based therapy  in the metastatic setting [11,12] . 
Resistance to antiestrogen treatment occur s commonly in pat ients and is an important therapeutic 
limitation. Approximately 30% of patients with metastatic disease have primary resistance to 
initial endocrine therapy and develop progressive disease (PD) within 6 months after init iation of 
antiestrogen therapy  [
10,13] . Many  other pati ents may init ially respond to hormonal therapy  but 
then develop se condary  resistance, defined as PD occurring more than 6 months after init iation of 
antiestrogen therapy  [
10,13] . The resistant tumors have not completely lost estrogen dependence 
and may  respond to an addi tional or al ternative antiestrogen therapy , such as the SERD 
fulvestrant, or to a combinat ion of ant ihormonals plus agents directed against cellular targ ets that 
mediate endocrine resistance [
14,15] . However, the duration of response or remissio n after 
subsequent , alternat ive therapy is often shorter than that achieved with earlier therapy [15]. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 20of 105
Protocol Incorporating Amendment No. 3 02 October 2017
4.1.2 Study Drug: MLN0128
4.1.3 Nonclinical Experience
MLN0128 (also known as TAK -228 and INK -0128) i s an orally available, potent, and highly  
select ive ATP -competit ive inhibitor of mechanist ic target of rapamycin (mTOR) kinase that 
exhibits dual specificit y against both target of rapamycin co mplexes 1 and 2 (TORC1 and TORC2 
[TORC1/2]). MLN0128 is a second -generat ion mTOR inhibitor that targets the kinase domain of 
the mTOR enzyme to suppress TORC1 and TORC2 funct ions. Currently the only mTOR inhibitor 
drugs ava ilable are the derivatives of rapamycin, called rapalogs, which are allo steric inhibi tors 
that target only  the TORC1 com plex. 
MLN0128 select ively and potently inhibited the mTOR kinases (1 nM) in in vitro studies, but 
relative to mTOR inhibit ion, MLN0128 had >100 -fold less potency  on class I 
(phospho inosit ide-3-kinase [PI3K] iso forms α, β, ɣ, δ), class II (PI3KC2α and PI3K2Cβ), and 
class III (VPS34) PI3K family members. MLN0128 inhibited (>80%) the biochemical act ivity of 
5kinases (mTOR, DNA -PK, PDGFRα, F lt3, and CK1 epsilo n kinases) out of a panel o f 
222protein kinases. Out of a panel of 402 dist inct kinases, MLN0128 inhibited the ligand binding 
of only 10 receptor and intracellular protein kinases (ACVR1, BMPR1B, CSF1R, CSNK1D, 
CSNK1E, DDR1, MEK1, MEK2, PDGFRα, and RIPK2). MLN0128 also displayed potent 
cellular inhibit ion of both the TORC1 and TORC2 pathway  with cellular pharmacodynamic 
concentration producing 50% inhibit ion concentratio n values of less than 10 nM. 
MLN0128, administered orally (PO) in m ultiple hum an tum or xenograft m ouse m odels, inhibited 
angiogenesis and tumor growth by inhibit ing mTOR signaling at plasma concentrations associated 
with in vitro inhibit ion of mTOR in a dose -and time -dependent m anner. These effects display a 
clear pharma cokinet ic (PK) -to-pharmacodynamic relat ionship [16].MLN0128 inhibit s both the 
phosphorylat ion of S6 and 4E -BP1, the downstream substrates of TORC1, and select ively inhibit s 
serine/threonine -specific protein kinase (AKT) phosphorylat ion at Serine 473 (S473), as 
evidenced by decreased pAKT, the downstream substrate of TORC2 [
16-18] .MLN0128 inhibits 
mTOR signaling and has demo nstrated anticancer activit y against a number of human so lid tumor 
cell-line xenograft mouse models, including phosphatase and tensin ho mo
log (PTEN) mutant 
endo metrial, breast, and renal cell carcino mas.
4.1.3.1 Clinical Experience w ith MLN0128
The first -in-human, phase 1 study  of single -agent MLN0128 is current ly ongo ing in pat ients with 
advanced so lid malignancies (Study  INK128 -001). In the dose -escalation phase of this study, 
4dosing schedules were studied : daily  dosing (QD) (31 pati ents), 3 times daily  dosing (QD×3) 
(33patients), 5 times daily dosing (QD)×5 (22 patients), and weekly dosing (QW) (30 patients). 
Based on the safet y profile, PK/pharmacodynamics, and preliminary  efficacy  during the 
dose-escala tion phase, MLN0128 dosing regimens of 5 mg QD and 40 mg QW were selected for 
further evaluation in the expansio n phase in patients with renal cell carcino ma, endo metrial cancer, 
or bladder cancer. The QW schedule started at 40 mg but was subsequent ly redu ced to 30 m g due 
to poor l ong-term tolerabili ty requi ring high rates of dose modificat ion and interruption. As o f a 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 21of 105
Protocol Incorporating Amendment No. 3 02 October 2017
March 2015 data cutoff, the top 5 drug -related adverse events (AEs) by frequency were fat igue 
(67%), nausea (61%), hy perglycemia (59%), vomi ting (49%), and stomat itis (46%), consistent 
with other agents that inhibit the PI3K/AKT/mTOR pathway . Preliminary signs of ant itumor 
activit y have been seen in an assessment of 70 evaluable pat ients with bladder, endo metrial, and 
renal cell carcino ma that have been treated with MLN0128 either on daily or once weekly dosing 
schedules. Three partial responses (PRs) and 5 patients with stable disease (SD) ≥6 months were 
observed amo ng patients treated with daily MLN0128 compared to 1 complete response (CR), 
2PRs, and 3 patients with SD ≥6months observed in pat ients treated with weekly MLN0128 [19]. 
Another phase 1 study  of single -agent MLN0128 has been completed in patients with relapsed or 
refractory  multiple myel oma or Waldenström macroglobulinemia (Study  INK128 -002). The AE 
profile observed in this study  was also consistent with other drugs of the same class, and while 
there was some preliminary antitumor activit y in this pat ient populat ion, further development in 
this indicat ion is not being evaluated at this time [
20]. A combinat ion study  evaluat ing the use of 
MLN0128 in co mbinat ion with pacli taxel wi th or wi thout trastuzumab in patients with advanced 
solid tumors (Study  INK128 -003) has been co mpleted. MLN0128 was generally well tolerated in 
combinat ion with weekly paclitaxel while exhibit ing promising preliminary therapeutic activit y.
The effect of MLN 0128 on the corrected QT interval (QTc) in pat ients with advanced so lid tumors 
has been tested in the ongoing, single -arm, designated QTc study  (Study  C31002). Study  C31002 
has completed enro llment and the primary analysis of the effect of a single dose of 40mg 
MLN0128 on the QT/QTc interval in patients with advanced solid tumors has been concluded. The 
study  resul ts indicate that treatm ent wi th MLN0128 is not associated with clinically meaningful 
effects on the overall electrocardiographic safet y profile.
Milled MLN0128 is being invest igated either as a single agent or in co mbinat ion with paclitaxel in 
an addit ional phase 1 study  in pat ients with advanced solid tumors (Study  MLN0128 -1004). 
Study MLN0128 -1004 also invest igates the effects of food on MLN0128 exposures. In addit ion, 
combinat ions of milled MLN0128 with MLN1117 (an oral PI3Kα inhibitor) are being evaluated in 
a phase 1b study  in adult patients with advanced nonhematologic malignancies (Study  C32001), 
and co mbinat ions of milled MLN0128 with exeme stane or fulvestrant are being evaluated in 
patients wi th ER-positive/HER2 -negat ive breast cancer (Study  C31001; see Section 4.1.3.2 )
. 
4.1.3.2 Preliminary Data in Women With ER- Positive/HER2 -Negative Breast Cancer With
MLN0128 in Combination With Exemestane or Fulvestrant
The ongoing phase 1b/2 Study C31001 examines the safet y and efficacy of daily MLN0128 given 
in combinat ion with exemestane or fulvestrant therapy  in postm enopausal wom en wi th 
ER-positive/HER2 -negative advanced or metastatic breast cancer that has progressed on treatm ent 
with everolimus in combinat ion with exemestane or fulvestrant. The completed phase 1b porti on 
of the study  tested combinat ion doses of MLN0128 fro m 3 to 5 m g QD. As of November 2015, 9 
patients received treatm ent wi th MLN0128 pl us fulvestrant and 15 patients received MLN0128 
plus exemestane. Of 23 disease
-evaluable pat ients, 3 achieved a PR (all treated in co mbination 
with fulvestrant) and 13 had SD. The clinical benefit rate (CBR) at 6 m onths was 75% in the 
fulvestrant -treated pati ents and 40% in the exemestane -treated patients. Four patients were 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 22of 105
Protocol Incorporating Amendment No. 3 02 October 2017
ongoing. Based on the available preliminary data, the most common (occurring in ≥50% of 
patients) drug -related AEs included fat igue, nausea, di arrhea, pruri tus, and stomatit is.
The observed safet y profile of MLN0128 in co mbinat ion with either exemestane or fulvestrant 
was generally consistent with that of single -agent MLN0128. Per protocol, cohort safet y reviews 
were conducted with the invest igators during phase 1b, and 4 mg was selected as the starting dose 
of MLN0128 for the phase 2 portion of the study. As of 09 November 2015, 14 patients have bee n 
enrolled in the phase 2 part of the study.
4.1.3.3 Risk-Benefit Assessment for the Use of MLN0128 in ER -Positive/HER2 -Negative Breast 
Cancer
The most commo n treatment -emergent AEs (TEAEs) observed with MLN0128 are consistent wit h 
the pharmacodynamic mechanism o f mTOR inhibiti on that i s also seen wit h rapalogs (TORC1 
inhibit ion) or other dual TORC1/2 inhibitor s. The TEAEs observed across the MLN0128 
single- agent studi es include diarrhea, fat igue, vo miting, rash, mucosal inflammation, asthenia, 
dysgeusia, thrombocy topeni a, stom atitis, blood creatinine increased, hyperglycemia, nausea, 
anorexia, and decreased app etite. Further details are provided in the current version of the 
Invest igator’s Brochure.
During this study, risk mit igation strategies include, but are not limited to, strict applicat ion of the 
study  inclusio n and exclusio n criteria, frequent m onitoring of clinical and l aboratory  resul ts, 
guidelines for prophylaxis and management of potent ial toxicit ies, cri teria for dose m odificat ion, 
and regular monitoring of AEs and serious adverse events (SAEs) by  the sponsor.
Nonclinical data supporting the potential benefits of MLN0128 as an ant icancer therapy are 
summarized in Sect ion 4.1.3 . Observed indicat ions of clinical activit y of the combinat ion of 
fulvestrant+MLN0128 are presented in Section 4.1.3.2 .
4.2 Rationale for the Proposed Study
Approximately  70% of  breast cancers express hormo ne receptors, either PgR or ER [8]. 
Historically, s ingle -agent endocrine therapy has been the cornerstone of treatment for patients with 
ER/PgR -positive advanced breast cancer. Tamoxifen, a SERM that exhibits antagonist ic act ivity 
against the ER in breast tissue, and nonsteroidal AIs such as letrozole and anastrozole, which block 
the conversio n of androgenic steroids into estrogenic steroids, have routinely been used in 
successio n in the adjuvant and/or the first -line setting of advanced and/or metastatic 
ER/PgR -positive breast cancer. In fact, a lack of co mplete cross
-resistance between steroidal and 
nonsteroidal AIs has been demonstrated in several trials [21,22] .
An alternate second
-line or subsequent antihormonal treatment option is the SERD fulvestrant, 
which is current ly indicated for the treatment of postmenopausal wo men wit h metastatic hormone 
receptor -positive breast cancer following the failure of ant iestrogen therapy . Fulvestrant provides 
a distinct mechanism of act ion from AIs by  direct ly targeting ER for proteasomal degradat ion, 
which downregulates E2F transcript ion and thereby the proliferat ion signal.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 23of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Preclinical data suggest that breast cancer ce lls critically rely on PI3K -mTOR signaling for 
survival after complete abrogation of ER signaling [23]. Data from a study  with fulves trant 
administered 500 mg monthly to patients with recurrent hormone 
receptor -positive/HER2 -negative breast cancer indicate significant antitumor activit y after both 
antiestrogen and AI failure [
24].
Acquired resistance to antihormonal therapy  remains a maj or clinical  problem  in the treatm ent of  
patients wi th ER/PgR -positive breast cancer [
25]. Preclinical and clinical research focused on 
mechanisms of resistance has confirmed that various signal transduction pathways are ac tivated in 
breast cancer cells to escape the effect of endocrine therapy . In particular, activation o f the 
PI3K/mTOR pathway was ident ified as a key adaptive change driving acquired resistance to 
endocrine therapy. In addit ion, a strong link between prolif erative properties and the emergence o f 
horm one
-independent breast cancer cells has been ident ified [26,27] . These results suggested that 
simultaneous inhibit ion of ER and either PI3K/mTOR signaling or cell cycle regulat ion coul d 
prevent or delay  the emergence of horm one
-independent breast cancer cells.
A strategy  of targeting both ER and mTOR was tested in the BOLERO -2 study  through the 
addition of  everolimus (an mTOR inhibitor) to the steroidal AI exemestane. The combinat ion 
significant ly improved progression -free survival (PFS) in wo men with advanced 
ER-positive/HER2 -negative breast cancer after failure of tr eatment with letrozole or anastrozole 
[28] and led to the US Food and Drug Administration (FDA) approval of evero limus in this setting 
in 2012. Of note, the BOL ERO -2 study  primarily included pat ients whose disease recurred during 
or soon after antihormonal therapy, a population that was thought to be more sensit ive to combined 
ER/m TOR inhibit ion than patients who are naive to endocrine therapy or who progress aft er a long 
treatm ent-free interval. The HORIZON trial, in which wo men wit hout prior ant ihormonal therap y 
were treated either with single -agent letrozole or with the combinat ion of letrozol e plus the rapalog 
temsirolimus, failed to show improvement in PFS wi th the combinat ion (median PFS=9 mo nths 
for both groups; hazard ratio [HR] 0.90) [
29].
In February  2015, a combinat ion of the nonsteroidal AI letrozole plus the C DK4/6 inhibitor 
palboci clib was approved by the FDA for the treatment of postmenopausal wo men with 
ER-positive/HER2 -negative advanced breast cancer as init ial endocrine -based therapy  for thei r 
metastati c disease. The resul ts of the PALOMA -1 study  on which this approval was based 
demonstrated that the addit ion of palbociclib to letrozole significantly improved PFS (20.2 vs 
10.2 months; HR 0.488) in advanced ER -positive/HER2 -negat ive breast cancer [
12]. 
Another potentially beneficial co mbinat ion is the ER
-targeted SERD fulvestrant+everolimus (an 
mTOR inhibitor that targets the TORC1 complex). This co mbinat ion has shown efficacy in 
postm enopausal wom en after failure of AI treatment similar to that of the combinat ion of 
tamoxifen wit h everolimus (median t ime to progressio n [TTP] 7.4 months) [30]. Furthermore, the 
combinat ionof fulvestrant and a dual TORC1/TORC2 inhibitor induced significant ly higher rates 
of tumor cell death when compared to the combination of fulvestrant+everolimus [
27,31] , 
suggest ing synergist ic effects on tumor cell death through a more complete inhibit ion of 
mTOR-related survival signaling in the presence o
f complete ER abrogation by fulvestrant. These 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 24of 105
Protocol Incorporating Amendment No. 3 02 October 2017
data s uggest that by  simultaneously  targeting both the ER and survival pathways, there is a 
synergistic effect on tumor cell death. 
Collect ively, these data suggest that the combinat ion of fulvestrant+MLN0128 may improve the 
outcom e of patients with ER-positivebreast cancer that has progressed on ant iestrogen directed 
antihormonal therapy. The goal of this study is to test the hypothesis that dual TORC1/2 inhibit ion 
in combinat ion with fulvestrant has the potential to overcome endocrine therapy  resistance in 
ER-positive breast cancer through the inhibit ion of growth and survival o f tumor cells as well as 
the em ergence of resistant cells fo llowing therapy  with AI or AI combined wit h CDK4/6 
inhibitors. 
RATIONALE FOR SELECTED DOSES AND SCHEDULES OF MLN0128
The sel ected doses and schedules of 4 mg QD (Arm B) and 30 mg MLN0128 QW (Arm C) to be 
given in co mbinat ion with fulvestrant are based on the findings from 3 studies: 
Studi esINK128- 001, MLN0128-1004, and C31001.
Study  INK128 -001 was the first- in-human study  of M LN0128. Study  INK128 -001 was an 
open -label study  designed to determine the maximum tolerated dose and to ident ify dose- limit ing 
toxicity (DLT) f or oral  administrati on of  single -agent unmilled MLN0128 and to characterize the 
safet y and tol erabilit y of escal ating doses of MLN0128 in patients with advanced solid tumors. In 
this study , 116 pati ents wi th advanced solid tumors received single -agent MLN0128 (2 to 40 mg 
via 4 dosing schedules) in the dose escalation phase.
Doses of 40 mg QW, 30 mg QW, and 5 mg QD w ere further evaluated in an addit ional 82 patients 
in the expansio n phase, where 30 mg QW and 5 mg QD were selected as the recommended phase 2 
doses and schedules of MLN0128 for further development.
Weekly Dosing
Scale-up m anufacturing of MLN0128 required the introduction o f a physical milling step to 
control  parti cle size distribut ion of MLN0128 drug substance. Wit h the introduction of milled 
MLN0128, the recommended dose to be used in Arm C of this study  (30 m g milled MLN0128 
QW) was further confirmed in Study  MLN0128 -1004 ( Table 4.a). A total of 14 patients were 
enrolled and assigned, sequent ially, to 2 QW dosing cohorts. PK, safet y, and tolerabilit y were 
assessed.
Table 4.a DLT Observed With Weekly MLN0128 in Study MLN0128 - 1004
Dose of Milled MLN0128 Number of Evaluable Patients DLTs Observed in Cycle 1
20 mg QW 6 None
30 mg QW 6 None
DLT=dose -limiting toxicity , QW=once weekly.
As none of the patients in eit her dose cohort experienced DLT in Cycle 1, a dose of 30 mg 
MLN0128 QW was selected for further development. No clinically meaningful differences in PK 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 25of 105
Protocol Incorporating Amendment No. 3 02 October 2017
of MLN0128 were noted between the unmilled MLN0128 (Study  INK128 -001) and milled 
MLN0128 (Study  MLN0128 -1004) when given QW. The tolerabilit y of 30 m g milled MLN0128 
QW in co mbinat ion with fulvestrant will be tested in a safet y lead-in of 6 patients in Arm C of this 
study  (as detailed in Sect ion
 7.1.2 ).
Daily Dosing
The recommended phase 2 dose of 4 mg milled MLN0128 QD in combinat ion with either 
exemestane or fulvestrant was determined in the phase 1b dose finding portion of Study  C31001 
(see Section 4.1.3.2 ). In the phas e 1b porti on of  the study , 12 pati ents were ini tially dosed in a 
safet y lead-in wit h 5 m g QD of the unmilled MLN0128 material in co mbinat ion with either 
fulvestrant or exemestane (6 patients each). No DLTs were observed during Cycle 1 of treatment; 
however , 6 of  the 12 pati ents di d requi re dose reductions in Cycles 2 and 3 (2 patients each), and 
1patient each in Cycles 4 and 7. In order to evaluate the safet y of milled MLN0128 material, 
escalat ion cohorts of 3 and 4 mg QD of the milled material were tested in combinat ion: 6 pati ents 
at the 3 m g dose (3 in co mbinat ion with exemestane and 3 with fulvestrant) and 6 patients at the 
4mg dose (all wit h exemestane). Of the 6 patients treated with 4 mg MLN0128 in combinat ion 
with exemestane, 1 patient experienced a DLT of nausea and diarrhea. After review of the data 
with the invest igators, including events occurring outside o f the DLT evaluat ion peri od, it was 
agreed to stop escalat ion and mo ve forward with 4 mg QD in the phase 2 portion of the study  (in 
combinat ion wi th either exemestane or fulvestrant), as well as in Study  C31006 (in combinat ion 
with fulvestrant).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 26 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
5.0 STUDY OBJECTIVES
5.1 Primary Objectives
The primary objectives are:
!To compare the PFS of patients treated with the combination of fulvestrant+daily MLN0128 
versus patients treated with single-agent fulvestrant.
!To compare the PFS of patients treated with th e combination of fulvestrant+weekly MLN0128 
versus patients treated with single-agent fulvestrant.
5.2 Secondary Objectives
The secondary objectives are:
!To compare secondary efficacy endpoints in patients treated with the combination of 
fulvestrant+daily MLN0128 versus patients treated with single-agent fulvestrant.
!To compare secondary efficacy endpoints in  patients treated with the combination of 
fulvestrant+weekly MLN0128 versus patients treated with single-agent fulvestrant.
!To assess the safety and tolerability of the combination of fulvestrant+MLN0128.
!To collect plasma concentration-time data with sparse PK sampling (combination 
fulvestrant+MLN0128 treatment arms [Arm B and Arm C] only), to contribute to future 
population PK analysis.
5.3 Health-Related Quality of Life Objective
The health-related quality of life (HRQL) objective is:
!To assess the HRQL and symptoms, as measured by the European Organization for Research 
and Treatment of Cancer QLQ Questionnaire, version 3.0 (EORTC QLQ-C30) and the EORTC QLQ Breast Cancer-Specific Questionnaire (EORTC QLQ-BR23), among the 
3 treatment arms.
5.4 Exploratory Objectives
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseMLN012LN01
weekly Mweekly 
d with thwith t
singlesingle -a
treated treated
ated withed w
mbinatiombinat
a wiwththiishh
[Arm[Arm Bm
of Life Of Life
ife (HRfe (H
and symnd sym
Cancer Qancer 
reast Careast C
rms.ms.
ploratorlorat
perty of Taked
MLN0128 (TAK-228)
Study No. C31006 Page 27 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usems of Use
MLN0128 (TAK-228)
Study No. C31006 Page 28 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
6.0 STUDY ENDPOINTS
6.1 Primary Endpoint
The primary endpoint is:
!PFS.
6.2 Secondary Endpoints
The secondary endpoints are:
!Overall survival (OS).
!TTP.
!Objective response rate (ORR); defined as CR ∀PR per Response Evaluation Criteria in Solid 
Tumors (RECIST) Version 1.1 [1].
!CBR; defined as CR ∀PR∀SD with SD of any duration, and CBR with SD duration of at least 
6m o n t h s .  
!The number and percentage of patients with TEAEs.
6.3 Health-Related Quality of Life Endpoints
The HRQL endpoints are:
!Changes from Baseline in functional and symptom scores, and global health status and quality 
of life score from the EORTC QLQ-C30 questionnaire.
!Changes from Baseline in functional and symptom scales from the EORTC QLQ-BR23 
questionnaire.
6.4 Exploratory Endpoints
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Usense Evanse Ev
, and CB, and CB
EAEs.AEs.
pointsoints
nal andnal an
QLQQLQ -C
functunctioi
EndpoiEndp
operty of Takeda: For No
MLN0128 (TAK -228)
Study No. C31006 Page 29of 105
Protocol Incorporating Amendment No. 3 02 October 2017
7.0 STUDY DESIGN
7.1 Overview of Study Design
7.1.1 Enrollment and Randomization
This is an open -label, rando mized, 3 -arm, mult icenter, phase 2 study  of the efficacy and safet y of 
the combination o f fulvestrant+daily MLN0128 compared with single -agent fulvestrant, and the 
combinat ion of fulvestrant+weekly MLN0128 compared with single -agent fulvestrant, in the 
treatm ent of postm enopausal  wom en wi th advanced or m etastati c ER -positive/HER2- negative 
breast cancer that has progressed durin g or after AI therapy . Patients who provide written informed 
consent and meet all eligibilit y criteria will  be randomized 1:1:1 to 1 of 3 treatment arms via the 
interact ive response techno logy (IRT):
Arm A, single -agent fulvestrant: fulvestrant, 500 mg intramuscularly (IM), on Cycle 1 Days 1 
and 15 (l oading regimen), and then on Day  1 of each subsequent 28 -day cycle.
Arm B, combinati on of  fulvestrant+daily  MLN0128: fulvestrant as above and MLN0128, 
4mg PO QD continuously.
Arm C, combinati on of  fulvestrant+ weekly MLN0128: fulvestrant as above and MLN0128, 
30mg PO QW continuously.
Patients will  be stratified at randomizat ion according to the presence or absence of visceral 
metastasis, previous sensit ivity to hormonal therapy, and previous exposure to CDK 4/6 inhibitors. 
Visceral  metastasis i s defined as all lesio ns not included in the fo llowing list: breast, skin, 
subcutaneous tissue, lymph node or bone. Previous sensit ivity to hormonal therapy is defined as at 
least 24 months of endocrine therapy before recu rrence in the adjuvant setting (ie, in patients who 
have not received previous endocrine therapy  in the m etastati c setting) or a response or 
stabilization for at least 24 weeks of the most recent endocrine therapy for advanced/metastatic 
disease.
Enrollmen t will be m anaged via the IRT to ensure that approximately 40% of enrolled patients 
have previously received a CDK4/6 inhibitor in combinat ion with an AI. Enrollment of 
non-CDK4/6 pretreated patients may  be stopped in the case that 60% or greater of enro llment has 
occurred with only  non-CDK4/6 pretreated patients.
Enrollment is defined as being rando mized to a treatment arm . The first dose of study drug must be 
administered within 5 days after randomizat ion on study. Patients will receive study medicat ion(s) 
in 28 -day cycles. The study  design is displayed in Figure 7.a.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 30of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Figure 7.a C31006 Study Design
DC for disease 
progression            
DC for    
othe r reasons Scre ening
&
Confirm
EligibilityRANDFulvestrant  
daily MLN0128
Fulvestrant 
weekly MLN0128 (a)
Single -agent     
fulvestrant EOT
visit
Single -agent 
fulvestrant only:
DC for
disease progressionPrecrossover
EOT visitRANDCrossover therapy optionFulvestrant 
daily MLN0128
Fulvestrant 
weekly MLN0128OS 
Follow -up
PFS 
Follow -upEOT
visitDC for disease 
progr ession            
DC for    
othe r reasons OS 
Follow -up
PFS 
Follow -up
DC=discontinuation, EOT=End-of-Treatment, OS=overall survival, P FS=progression -free survival, 
RAND=randomization.
(a) The weekly dose of 30 mg MLN0128 will be tested in a safety lead -in of 6 patients in this study (as detailed in 
Section 7.1.2) to ensure safety and tolerabil ity of the combination with fulvestrant.
7.1.2 Weekly MLN0128 Dose Confirmation (Arm C)
This will be the first study  in which weekly MLN0128 will be combined with fulvestrant. 
Therefore, a safet y and tol erabili ty assessment will be performed for patients treated wit
h 
fulvestrant+weekly MLN0128 (30 mg) after the first 6 DLT -evaluable patients have completed 
1cycle (i e, Cycle 1 Day  28). Pati ents will  be considered evaluable for DLT assessment if they  
have completed all scheduled study visits during the first cycle and have received at least 3 (75%) 
of the 4 planned doses of MLN0128 in co mbination with fulvestrant in Cycle 1. The 30 mg starting 
dose for weekly MLN0128 will be confirmed or adjusted based on the DLTs observed (see 
Secti on9.3for DLT definit ions):
If ≤1 DLT occurs, the MLN0128 dose for this treatment arm will remain the same (ie, 30 mg 
weekly MLN0128, in combinat ion with fulvestrant).
If ≥2 DLTs occur, all patients subsequently randomized to this treatment arm will receive a 
starting dose of 20 mg w eekly  MLN0128, in combinat ion with fulvestrant. The starting dose 
reducti on will be documented in formal written communicat ion to all study  sites.
DLTs will be assessed and co llected in the database for the first 6 evaluable pat ients in Ar m C o nly 
(fulvest rant+weekly MLN0128). DLTs are not applicable to patients in Arm A or Arm B at any 
time in the study , or to pati ents in Arm  C who are not included in the safet y and tol erabili ty 
assessment, or to cross -over patients. Enrollment of pat ients into the study w ill cont inue while this 
safet y and tolerabilit y assessment i s conducted. For any  patients init ially assigned to the 30 mg 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 31 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
QW starting dose, the MLN0128 dose may be decreased if necessary per the dose modification 
criteria in Section 9.4.
7.1.3 Study Eval uations (All Treatment Arms)
Safety assessments (including AEs, SAEs, laboratory assessments, vital signs, electrocardiograms 
(ECGs), Eastern Cooperative Oncology Group [ECOG] performance status, and weight) will be 
performed throughout the treatment period, including the End-of-Treatment (EOT) Visit, to 
evaluate the safety and tolerability of MLN0128. Toxicity will be evaluated according to National 
Cancer Institute Common Terminology Criteria for Adverse Events (N CI CTCAE), Versio n 4.03, 
effective date 14 June 2010 [32].
HRQL will be assessed via the EORTC QLQ-C30 and EORTC QLQ-BR23 instruments 
throughout the treatment period, including the EOT Visit.
Radiological tumor evaluations (computed tomogra phy [CT] scan with intravenous [IV] contrast 
or magnetic resonance imaging [MRI] as clinically indicated) of the chest, abdomen, and pelvis 
will be used to evaluate disease response according to RECIST guidelines (Version 1.1) [1]. 
Radiographic tumor evaluations will be performed by  the investigator at the time points specified 
in the  Schedule of Events.
Blood samples will be collected (from patients in the combination fulvestrant+MLN0128 
treatment arms [Arm B and Arm C] only) to c ontribute data to an overall population plasma PK 
analysis, in combination with data from  the other clinical studies of MLN0128.
Patients will receive study medication(s) unt il PD, unacceptable toxicity, or withdrawal of 
consent. Patients who discontinue study medication will complete an EOT Vis it 30 to 40 days after 
the last dose of study drug. The EOT Visit should be conducted before the initiation of subsequent 
anticancer therapy, even if it occurs sooner than 30 days after the last dose of study drug. Patients 
who discontinue study treatment for reasons other than PD will continue to have PFS follow-up 
visits every 2 months (±1 week) for the first 6 months after the EOT Visit and then every 3 months 
(±1 week), until PD or start of another anticancer therapy, whichever occurs first. After PD or start 
of another anticancer therapy, patients will be followed for survival every 6 months (±1 week).
7.1.4 Potential for Crossover Treatment
Patients in the single-agent fulvestrant arm (Arm A) who have radiographically confirmed PD may 
be allowed to receive crossover treatment with the combination of fulvestrant+MLN0128 (see 
Figure 7.a) . Once documented PD has been confirmed, patients referred for crossover will CCI
Property of Takeda: For Non-Comected (fected (
and Armnd A
ion witon wi
eive studeive stu
nts whots wh
se of stuof st
cer theraer ther
discontdiscon i
itts evers ev
(±1 we(±1 w
ofofanaffand Subject to the Applicable Terms of Usediogramdiogram
ht) will ) will
Visit, toVisit,
rding tording t
CAE), VAE), 
BR23 inBR23 i
an witn wit h
) of the ) of th
CIST guCIST gu
he invee inv
mmercial Use Only a
MLN0128 (TAK -228)
Study No. C31006 Page 32of 105
Protocol Incorporating Amendment No. 3 02 October 2017
complete the Precrossover EOT Visit as soon as possible (see the Schedule ofEvents for details). 
Patients m ust meet all applicable study  eligibilit y criteria at the time o f crossover (eg, the 
exclusio n for prior fulvestrant therapy  woul d not apply), and eligibilit y for crossover will be 
confirmed by the sponsor’s project clinician (or designee). Eligible pat ients will then be 
rando mized via the IRT in a 1:1 ratio to either fulvestrant+daily MLN0128 or fulvestrant+weekly 
MLN0128.
It is recommended that cros sover treatment begin within 28 days (+10days) after docum ented
disease progressi on (imaging date of PD), with the goal of maintaining the ongoing schedule of 
fulvestrant therapy  (ie,dosing every  28days). Whenever possible, MLN0128 should be init iated 
at the next scheduled dose of fulvestrant but only when th e patient has completed the pre crossover 
screening requirements and is eligible to continue. If the crossover treat ment cannot begin wit hin 
28days (+10 days) after docum ented PD ,contactthe medical mo nitor.
Patients m ay receive crossover treatm ent until they experience PD on crossover treatment, 
unacceptable toxicit y, they withdraw consent, or they are no longer cons idered by the investigator 
to be deriving clinical benefit from the crossover treatment.
Only the data collected during the study treatment in the init ial single -agent fulvestrant arm will be 
included in the planned efficacy and safet y analyses for the stu dy. After crossover treatment 
begins, safet y and efficacy  data will be collected (as detailed in the Schedule ofEvents ) and 
presented separately .
7.1.5 Potential for Single -Agent MLN0128 Dosing
If fulvestrant is discont inued for a patient in eit her combinat ion arm (Arm B o r Arm C), the patient 
may cont inue receiving MLN0128 at their current dose if, after discussio n between the 
investigator and sponsor, it is determined that the patient would derive benefit fro m continued 
treatm ent with single -
agent MLN0128 and there are no safet y concerns.
7.2 Number of Patients
Approximately  153 pati ents (51 pati ents per treatment arm) will be enrolled in this study  from 
approximately  65study  centers in North America and Europe. A patient is conside red to be 
enrolled in the study  when she has been rando mized into a treatment arm.
7.3 Duration of Study
Patients will  receive study  medicat ion(s) unt il PD, unacceptable toxicit y, or withdrawal of 
consent. Patients who discont inue study medicat ion will complet e an EOT Visit 30 to 40 days after 
the last dose of study drug. The EOT Visit should be conducted before the init iation o f subsequent 
anticancer therapy , even if it occurs sooner than 30 day s after the l ast dose of study  drug. Pati ents 
who discontinue stud y treatm ent for reasons other than PD will cont inue to have PFS fo llow-
up 
visits every 2 months (±1 week) for the first 6 months after the EOT Visit and then every 3 months 
(±1 week), until PD or start of another ant icancer therapy, whichever occurs first. After PD or start 
of another ant icancer therapy, patients will be fo llowed for OS every  6 months (±1 week).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 33of 105
Protocol Incorporating Amendment No. 3 02 October 2017
The accrual durat ion will be approximately 14 mo nths. A final analysis of PFS will be performed 
after the required number of events has been observ ed which is expected approximately 20 months 
after the first pati ent is rando mized. The study  will be cl osed approximately 20 months after the 
first pati ent is rando mized, or when the last patient discont inues study treatment.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 34of 105
Protocol Incorporating Amendment No. 3 02 October 2017
8.0 STUDY POPULATION
8.1 Inclusion Cr iteria
Each patient must meet all of the fo llowing inclusion criteria to be enrolled in the study :
1.Female patients aged 18 years or older who are postmenopausal. Postmenopausal is defined as:
Aged 55 years and 1 y ear or m ore of natural  amenorrhea pri or to Screening, or
Aged <55 years and 1 y ear or m ore of amenorrhea pri or to Screening, with a 
follicle -stimulat ing horm one level >40 m IU/mL and an estradio l level o f <20 pg/mL, or 
Surgical menopause with bilateral oophorectomy.
Note: Ovarian radiation or trea tment w ith a luteinizing hormone- releasing hormone 
agonist (goserelin acetate or leuprolide acetate) is not permitted for induction of ovarian 
suppression.
2.Histologically proven di agnosis of breast cancer wit h evidence of metastatic disease or 
locoregi onal recurrence , not am enable to resecti on or radi ation therapy  with curative intent.
3.Histological confi rmationand documentation of ER -positivestatus (≥1% posit ive stained 
cells) by local laboratory  testing utilizing an assay  consistent wi th local standards.
4.Histological or cy tological confirmat ion and documentation of HER2 -negative status by local 
laboratory  testing using cri teria in the Ameri can Soci ety of Oncol ogy (ASCO)/Co llege o f 
American Pathologists (CAP) Clinical Pract ice Guideline update [33].
5.Measureable disease defined as either of the fo llowin
g:
At least 1 extra -osseous lesio n that can be accurately measured in at least 1 dimensio n. The 
lesion must measure ≥20 mm wit h convent ional imaging techniques or ≥10 mm with spiral 
CT or MRI. Lymph nodes must be ≥1.5 cm  in the short axis to be considered measurable.
Bone l esions (ly tic or mixed [ly tic plus scleroti c]) in the absence of measurable disease as 
defined above.
Note: Patients w ith sclerotic/osteoblastic bone lesions only, in the absence of measurable 
disease, are not eligible.
6.PD during prior AI therapy  defined as:
Recurrence during or within 12 mo nths after complet ion or discont inuat ion of adjuvant 
therapy  or
Progression during or within 1 month after the end of therapy  in the metastati c setti ng.
Note: AI is not required to be the most recent therapy, but progression on AI and
progression on most recent therapy are both required for eligibility.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 35of 105
Protocol Incorporating Amendment No. 3 02 October 2017
7. Pat ients who have a history o f brain metastasis are eligible for the study provided that all of the 
following criteria are met: 
Brain metastases have been treated.
No evi dence of PD for 3 months before the first dose of study  drug.
No hem orrhage after treat ment.
Off dexamethasone treatment for ≥4 weeks before the first dose of study  drug.
No ongoi ng requirement for dexamethasone or antiepilept ic drugs.
8.ECOG performance status of 0 or 1 (refer to Appendix D).
9.Clinical laboratory  values as specified below wit hin 4 weeks before the first dose of study  
drug:
Bone m arrow reserve consistent with abso lute neutrophil count (ANC) ≥1.5 109/L; 
platelet count ≥100109/L; hemoglobin (Hgb) ≥9 g/dL.
Total  bilirubin ≤1.5 the upper limit o f the normal range (ULN), aspartate 
aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5 ULN ( ≤5ULN if liver 
metastases are present).
Creatinine clearance ≥40 mL/min based on Cockcroft -Gault estimate (refer to 
Appendix E) or based on a 12- or 24 -hour urine collect ion.
Fasting serum glucose ≤130 m g/dL and fast ing triglycerides ≤300 mg/dL.
10.Abilit y to swall ow oral  medicat ions, willingness to perform mucosit is prophylaxis, and 
suitable venous access for the study -required bl ood sam pling.
11.Voluntary  written consent must be given by the patient (or the patient’s legally acceptable 
representative) before performance of any study -related procedure that is not part of standard 
medical care, with the understanding that cons ent may be withdrawn at any  time without 
prejudice to the pati ent’s future medical care.
8.2 Exclusion Criteria
Patients m eeting any o f the following exclusio n criteri a are not to be enrolled in the study :
1.Prior therapy  with mTOR, PI3K, or dual  PI3K -mTOR inhib itors, AKT inhibitors, or 
fulvestrant.
2.Prior treatm ent wi th >1 line of chemotherapy  for metastati c breast cancer or for locoregi onal 
recurrence that was not amenable to resection or radiat ion therapy  with curative intent.
3.Experi enced PD on >2 endocrine the rapies for metastati c breast cancer or for locoregi onal 
recurrence that was not amenable to resection or radiat ion therapy  with curative intent.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 36of 105
Protocol Incorporating Amendment No. 3 02 October 2017
4.Life-threatening m etastati c visceral disease (defined as extensive hepat ic involvement or 
symptom atic pulmo nary lymphangit ic spread). Patients with discrete pulmo nary parenchymal 
metastases are eligible, provided their respiratory  function is not compromised as a result of 
disease.
5.Other clinically significant comorbidit ies, such as uncontrolled pulmo nary disease, active 
central  nervous system disease, active infect ion, or any other condit ion that could co mpromise 
the pati ent’s parti cipat ion in the study .
6.History  of any of the f ollowing wit hin the last 6 months before the first dose of study  drug :
Ischemic my ocardia l event, i ncluding angina requiring therapy  and artery  
revascularization procedures.
Ischemic cerebrovascular event, including transient ischemic attack and artery  
revascularization procedures.
Requi rement for inotropi c support (excl uding di goxin) or seri ous (uncontrolled) cardiac 
arrhy thmia (incl uding atrial  flutter/fibrillat ion, ventri cular fibrillat ion, or ventricular 
tachy cardi a). 
Placement of a pacemaker for control of rhy thm.
New York Heart Associat ion Class III or IV heart failure (see Appendix F).
Pulmo nary embo lism.
7.Significant active cardio vascular or pulmo nary disease, including:
Uncontrolled hypertensio n (ie, either systolic blood pressure >180 mm Hg or diastolic 
blood pressure >95 mm Hg).
Pulmo nary hypertensio n.
Uncontrolled asthma or oxy gen saturation <90% by  arteri al blood gas analysis or pul se 
oximetry  on room  air.
Significant valvular disease; severe regurgitation or stenosis by  imaging independent of 
symptom  control  with medical intervention; or history  of valve replacement.
Medically  significant (symptom atic) bradycardia.
History  of arrhy thmia requiring an implantable cardiac defibrillator.
Baseline prolongat ion of QTc (eg, repeated demonstration of QTc interval >480 msec, or 
history  of congeni tal long QT sy ndrome, or torsades de pointes).
8.Diagnosed wi th or treated for another malignancy within 2 years before the first dose of study 
drug, or previously  diagnosed wi th another m alignancy and have any  evidence of residual 
disease. Pati ents wi th nonmelano ma skin cancer or carcinoma in situ of any  type are not
excluded if they have undergone complete resection.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 37of 105
Protocol Incorporating Amendment No. 3 02 October 2017
9.Receipt before the first dose of study  drug of any  of the f ollowing:
Any invest igational agent wi thin 4 weeks.
Chem otherapy  within a period of time that is less than the cycle length used for that 
treatm ent (eg, within 3 weeks for fluorouracil, doxorubicin, or epirubicin or within 1 week 
for weekly chemotherapy ).
Previous endocrine therapy  is permitted without any  window.
Radiotherapy  within 2 weeks. All acut e toxi c effects, except toxicit ies not considered a 
safet y risk for the patient at the invest igator´s discretion, must be reso lved to Grade <1 per 
NCI CTCAE versio n 4.0.
Major surgery  or other anticancer therapy  not previously specified wit hin 4 weeks. All
acute toxi c effects, except toxicit ies not considered a safet y risk for the patient at the 
investigator´s discret ion, must be resolved to Grades <1 per NCI CTCAE version 4.0.
10.Chronic conco mitant therapy  with bone-targeti ng agents (eg, bisphos, denosumab) for the 
prevent ion of bone metastases. Conco mitant treatment with bone -targeting agents is permitted 
for treatm ent of osteoporosis or management of exist ing bone metastases if init iated at least 
4weeks before the first dose of study drug.
11.Requi rement for chronic use of systemic corticosteroids (either IV or oral steroids). Inhalers 
and low -dose repl acement therapy  are all owed.
12.Requi rement for daily or chronic use of a proton pump inhibitor (PPI). All pat ients are required 
to stop taking PPIs at least 7 day s before receiving the first dose of study  drug.
13.Manifestati ons of malabsorption due to prior gastrointest inal (GI) surgery, GI disease, or for an 
unknown reason that may alter the absorption of MLN0128.
14.Poorly controlled diabetes mellitus defined as glyco sylated hemoglo bin (HbA1c) >7%; 
patients wi th a history  of transient gl ucose intol erance due to corti costeroi d administrati on 
may be eligible if all other inclusio n/exclusio n criteria are m et.
15.Known human immunodeficiency virus infect ion.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 38of 105
Protocol Incorporating Amendment No. 3 02 October 2017
9.0 STUDY DRUG
9.1 Study Drug Administration: Fulvestrant Plus MLN0128
All protocol -specific criteria for administration of study  drug (MLN0128 or fulvestrant) must be 
met and documented prior to the first dose of study drug. Study  drug will be administered only  to 
eligible patien ts under the supervisio n of the investigator or ident ified subinvest igator(s).
For all treatment arms, fulvestrant (500 mg) will be administered IM, according to the current US 
Prescribing Informat ion (USPI) or the current Summary o f Product Characterist ics (Sm PC), on 
Cycle 1 Day s 1 and 15 (l oading regimen), and then on Day  1 of each subsequent 28 -day cycle. 
Fulvestrant will be administered at the study  site by  appropri ately trained clinical staff, under the 
supervisio n of the invest igator or ident ified sub investigator(s).
For Arm  B, daily MLN0128 will be administered on an empt y stom ach. It is recommended that 
each dose of MLN0128 be given PO with 8 ounces (240 mL) of water. Patients should be 
instructed to refrain fro m eating and drinking (except for water and prescribed medications) for 
2 hours before and 1 hour after each dose.
For Arm C, weekly MLN0128 will be administered with a light meal. Examples of a light meal are 
provi ded in Table 9.a. Patients shoul d begi n consuming the light meal no more than 30 minutes 
before taking the weekly dose of MLN0128. It is recommended that each dose of MLN0128 be 
given PO with 8 ounces (240 mL) of water.
Table 9.a Examples of a Light Meal
Low-Fat Breakfast Light Snack
Nutritional information Approximately 330 calories, with 9 g 
of fatApproximately 100 to 300 calories, with 1.5 g 
of fat
Example 2 slices of toast with 1 teaspoon of 
low-fat margarine, 1 teaspoon of jelly, 
and 8 oz of skimmed milk3.63 oz pudding cup or 1 slice of toast with 
1teaspoon of jelly and 8 oz of skimmed milk
Patients should be instructed to take MLN0128 at approximately the same t ime on each scheduled 
dosing day and not to take more than the prescrib ed dose at any  time. Pati ents shoul d swall ow the 
MLN0128 capsules whole and not chew, open, or manipulate the capsules in any way before 
swallowing. If a patient does not take their MLN0128 dose within 12 hours after the scheduled 
dosing t ime ( for patients in Ar m B) or within 24 hours after the scheduled dosing time (for patients 
in Arm C), then the dose should be skipped and considered a missed dose. Patients should record 
any missed doses in their dosing diary  (see Dosing Diary  Arm A and Dosing Di ary Arm B) and 
resum e drug administration at the next scheduled time wit h the prescribed dosage. Patients should 
be instructed not to take their MLN0128 dose at home on days they have a study visit at the clinic. 
The MLN0128 dose should be taken at the clinic afte r the requi red procedures are performed as 
described in the Schedule ofEvents .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 39of 105
Protocol Incorporating Amendment No. 3 02 October 2017
If severe emesis or mucosit is prevents the patient from taking scheduled doses, that dose will be 
skipped. If emesis occurs after MLN0128 ingest ion, the dose will not be readministered, and 
patients shoul d resume dosing at the next scheduled time wit h the prescribed dosage. Patients 
shoul d record the occurrence of the emesis in their patient dosing diary. Under no circumstance 
shoul d a patient rep eat a dose or double -up doses.
9.2 Reference/Control Therapy: Single -Agent Fulvestrant
Fulvestrant (500 mg) will be administered IM, according to the current USPI or SmPC, on Cycle 1 
Days 1 and 15 (loading regimen), and then on Day 1 of each subsequent 28 -day cycle. Fulvestrant 
will be administered at the study  site by  appropriately trained clinical staff, under the supervisio n 
of the invest igator or ident ified subinvest igator(s).
9.3 Definitions of DLT (Weekly MLN0128 Dose Confirmation)
Dose -limit ing toxicit ies ar e defined according to the AE profile observed during the first 28 days 
of study  drug administrati on as described below. Occurrence of DLTs in the first 6 evaluable 
patients in the combinat ion fulvestrant+weekly  MLN0128 treatm ent arm  (Arm  C) will  be 
review ed to eval uate the safet y and tol erabili ty of 30 m g weekly MLN0128 in combinat ion with 
fulvestrant (see Section 7.1.2 ):
If ≤1 DLT occurs, the MLN0128 dose for this treatment arm will remain the same (ie, 30 mg 
weekly MLN0128 in co mbinat ion with fulvestrant).
If ≥2 DLTs occur, all patients subsequently randomized to this treatment arm will receive a 
starting dose of 20 mg weekly MLN0128 in combinat ion with fulvestrant. The starting dose 
reducti on will be documente d in form al written communicat ion to all study  sites.
Toxicit y will be evaluated according to the NCI CTCAE, Version 4.03, effective 14 June 2010 
[32]. A DLT will be defined as any o f the following events that are considered by the invest igator 
to be at least possibly related to treatment with wee kly MLN0128 in combinat ion with fulvestrant:
Grade 3 or higher nonhematologic toxicit y, despi te adequate treatment, except for the 
following:
–Grade 3 hy perglycemia last ing ≤14 days (all pat ients should receive optimal ant iglycemic 
treatm ent, including insu lin).
–Grade 3 rash last ing ≤3 days (all pat ients should receive topical steroid treatment, oral 
antihistamines, and oral steroids, if necessary).
Grade 4 neutropenia last ing >7 days in the absence of growth factor support.
Grade 4 neutropenia of any durati on acco mpanied by fever ≥38.5°C and/or systemic infect ion.
Any other ≥Grade 4 hematologic toxicit y.
Inabilit y to administer at least 75% of planned doses of MLN0128 within Cycle 1 due to study 
drug-related toxicit y.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 40of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Any clinically  significant occurrence th at the investigator and sponsor agree would place 
patients at an undue safet y risk.
9.4 Dose Modification Guidelines
This sect ion describes dose modificat ion gui delines for MLN0128. Any  dose m odificat ions for 
fulvestrant should fo llow the gui delines provided in the current USPI or SmPC for fulvestrant.
MLN0128 should be administered QD or QW in 28 -day cycles, and dosing should cont inue unless 
the patient has a Grade 3 or higher MLN0128 -related event. In the case of mult iple less severe AEs 
occurring together fo r which, in the investigator’s judgment, the patient would benefit from a dose 
modificati on (ie, reduction or delay), dose modification may be considered. General guidelines for 
MLN0128 dose interruption and dose reduction are provided in Sect ion 9.4.1 and Section 9.4.2 . 
Detailed dose modification requirements for specific clinical events are provided in Section 9.8.
Dose m odificat ions (including dose interruption, reduction, or discont inuat ion) for fulvestrant, if 
necessary , shoul d be based on the current fulvestrant SmPC or USPI, local inst itution standards, 
and the invest igator’s best clinical judgement. In the single -agen t fulvestrant arm  (Arm  A): if 
fulvestrant is discontinued for a patient in the single -agent fulvestrant arm due to PD, the patient 
may be eligible for crossover treatment as described in Sect ion 7.1.4 ;
 if fulves trant i s discont inued 
due to safety  concerns or intol erabili ty, the pati ent will  com plete the EOT Visit and be followed 
for PFS/OS as described in Section 10.7. If fulvestrant is discontinued for a patient in ei ther of the 
combinat ion treatment arms (Arm B or Arm C), the patient may be eligible to continue receiving 
MLN0128 at their current dose as described in Section 7.1.5 . If MLN0128 is discont inued for a 
patient in either of the combinat ion treatment arms (Arm B or Arm C), the pati ent will co mplete 
the EOT Visit and be fo llowed for PFS/OS as described in Sect ion
 10.7.
9.4.1 MLN0128 Dose Interruption
Administrati on of  MLN0128 sh ould be wi thheld (for up to 3 weeks) for treatment- related 
toxicities that are Grade 3 or higher despite supportive treatment per standard clinical practice. 
MLN0128 may  resume treatm ent at a l ower dose (as detailed in Sect ion
 9.4.2 ) if the toxicit y 
resolved to baseline level or Grade 1 (or Grade 2 for hy perglycemia or rash, as detailed in 
Secti ons9.8.1 and 9.8.4 , respectiv ely). If the event does not resolve to baseline level or Grade 1 
within 3 weeks, MLN0128 will be discont inued permanent ly and the patient will co mplete the 
EOT Vi sit and be foll owed for PFS/OS as described in Sect ion
 10.7.
The fo llowing nonhematologic toxicit ies attributed to MLN0128 would notrequire dose 
interrupti on:
Grade 3 or higher nausea and/or emesis in the absence o f optimal ant iemetic prophylaxis. 
Optimal antiemet ic prophylaxis is defined as an antiemet ic regimen that emplo ys both a 
5-hydroxy tryptamine antagonist and a corticosteroid given in standard doses and according to 
standard schedules.
Grade 3 or higher diarrhea that occurs in the absence of optimal supportive therapy.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 41of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Grade 3 fat igue.
9.4.2 MLN0128 Do se Reduction
As detailed in Sect ion 9.4.1 , MLN0128 administration should be wit hheld for treatment -related 
AEs that are Grade 3 or higher despite supportive treatment per standard clinical pract ice. If the 
event resolves to Grade 1 or to baseline values within 3 weeks of interrupting treatment, then the 
patient may  resume study  treatm ent at a dose reduced by  1 level ( Table 9.b). If a pati ent does not 
tolerate the reduced dose, then the invest igator and the project clinician should discuss whether the 
patient woul d benefit from a further dose reduction.
Table 9.b Dose Reductions for MLN0128
Dose Level Daily Dose Regimen Weekly Dose Regimen
0 4 mg QD 30 mg QW
1 3 mg QD 20 mg QW
2 2 mg QD 15 mg QW
3 2 mg, 5 days on and 2 days off per week 10 mg QW
QD=once daily, QW=once weekly.
When a dose reduction of MLN0128 is required, no re -escalat ion of dose will be permitted.
9.4.3 Discontinuation of MLN0128
If MLN0128 administration is delayed for more than 3 weeks (21 consecut ive days) due to study 
drug-related toxicit y despi te supportive treatment per standard clinical pract ice, or more than 
3dose reductions of study  drug are requ ired in a patient, MLN0128 will be permanently 
discontinued and the patient will co mplete the EOT Visit and be fo llowed for PFS/OS as described 
in Section 10.7.
9.5 Excluded Concomitant Medications and Procedures
9.5.1 Excluded Concomitant Medications and Procedures for Single -Agent Fulvestrant 
Treatment Arm (Arm A)
Refer to the current fulvestrant USPI or SmPC for excluded medicat ions for pati ents receiving 
single- agent fulvestrant in this study .
In addit ion, these specif ic excl usions also apply  to Arm  A (single -agent fulvestrant):
Other invest igational agents including mTOR, PI3K, dual PI3K -mTOR, and AKT inhibitors.
Other anticancer therapies, including chemotherapy, immunotherapy , radi oimmunotherapy , 
targeted agents, rad iation, or surgery . Pati ents can have palliat ive radiat ion or surgery  during 
the study  for pre -exist ing lesio ns.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 42of 105
Protocol Incorporating Amendment No. 3 02 October 2017
9.5.2 Excluded Concomitant Medications and Procedures for Combination MLN0128 Plus 
Fulvestrant Treatment Arms (Arm B and Arm C)
Refer to the current fulvestrant USPI or SmPC for excluded medicat ions for pati ents receiving 
fulvestrant in this study .
In addit ion, the fo llowing medicat ions, therapies, and procedures are prohibited during the study  
for pati ents receiving combinat ion treatment:
Other invest igational agents including mTOR, PI3K, dual PI3K -mTOR, and AKT inhibitors.
Other anticancer therapies, including chemotherapy, immunotherapy , radi oimmunotherapy , 
targeted agents, radiat ion, or surgery . Pati ents can have palliat ive radiat ion or surgery  duri ng 
the study  for pre -exist ing lesio ns.
Systemic corti costeroi ds (ei ther IV or oral  steroi ds), unl ess necessary  for treatm ent of a study  
drug-related AE (eg, rash). Inhalers and low -dose repl acement therapy  are all owed.
Strong cytochrome P450 (CYP) 1A2 inhi bitors and CYP inducers should be administered with 
cauti on and at the discret ion of the invest igator (see Appendix Gfor a list of these agents).
Concomitant administration of any PPI is not permitted during the study . All patients are 
requi red to stop taking PPIs at least 7 days before receiving the first dose of study  drug. 
Examples of PPIs include o meprazo le, esomeprazole, pantoprazole, lansoprazole, and 
rabeprazo le.
Histamine H2 receptor antagonists may be allo wed if n eeded, provi ded that the histamine H2 
receptor antagonist is not taken within 12 hours before or within 6 hours after study  drug 
administration. Patients receiving histamine H2 receptor antagonists before enro llment must 
stop using these medicat ions for atleast 24 hours before their first dose of study  drug. 
Examples of histamine H2 receptor antagonists include ranit idine, famot idine, and nizati dine.
Cimet idine, a m oderate CYP1A2 inhibitor, is not recommended as a first choice H2 receptor 
antagonist (see Appendix G).
Administrati on of  neutralizing antacids and calcium preparat ions is permitted except fro m 
4hours before until 2 hours after study  drug administration. Some ant igas preparations may 
also have antacid pr operti es and should also not be permitted from 4 hours before until 2 hours 
after study  drug administrati on.
9.6 Permitted Concomitant Medications and Procedures (All Treatment Arms)
All prescript ion and over -the-counter medicat ions, including influenza vaccin es, taken by a patient 
from the first dose of study  drug through 30 days after the last dose will be recorded on the 
designated electronic case report form (eCRF).
Prophylactic use of ant iemetic, ant inausea, and ant idiarrheal medications is encouraged, and these 
may be administered before the first dose of study  drug, as needed throughout the study  before 
each dosing, and as clinically indicated per standard practice.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 43of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Concomitant treatment with bone -targeting agents (eg, bisphos, denosumab) is permitted for
treatm ent of osteoporosis or management of exist ing bone metastases if init iated at least 4 weeks 
before administration of the first dose of study  drug. To minimize confounding factors that may 
contribute to assessment of potential drug -related toxi cities, the dosage of any ongo ing 
bone -targeting agents shoul d not be changed, and no new bone -targeting agents shoul d be init iated 
during Screening (within 4 weeks before the first dose of study  drug) or during Cycle 1.
Other medications considered necessary  for the safety  and well being of the patient may  be 
administered at the discret ion of the invest igator. Any conco mitant m edicati ons added or 
discontinued during the study  shoul d be recorded on the eCRF.
9.7 Precautions and Restrictions
The use of live vaccines and close contact with those who have received live vaccines should be 
avoided during treatment with study  drug. Examples of live vaccines include the intranasal 
influenza, measles, mumps, rubella, oral polio, Bacillus Calmette -Guerin, y ellow fever, varicel la, 
and TY21a ty phoid vaccines.
No di etary  restri ctions will be imposed on study  patients.Patients are required to fast for glucose 
monitoring (refer to Section 9.8.1 and Section 10.4.16 ). Patients receiving daily MLN0128 in 
ArmB shoul d refrain f rom eating or drinking for 2 hours before and 1 hour after each dose (per 
Secti on9.1). 9.1).
Patients who show evidence of hyperglycemia during the study  shoul d be encouraged t o follow a 
low carbohy drate di et.
Patients shoul d be encouraged to drink at least 20 ounces of fluids a day , especially  on days 
requi ring fasting (per protocol), with administration of IV fluids in the clinic as indicated to avoid 
dehydrat ion.
9.8 Management o f Clinical Events
Detailed MLN0128 dose modificat ion and preventio n/prophylaxis guidelines for specific clinical 
events are provided in the fo llowing secti ons. General  guidelines for MLN0128 dose interruption 
and dose reduction are provided in Sect ion 9.4.1 and Section
 9.4.2 . 
9.8.1 Management of Hyperglycemia
On the basis of the clinical experience in MLN0128 trials, most episodes of hyperglycemia 
observed occurred within t he first 60 day s after initi ation of treatment with MLN0128 and have 
been eit her Grade 1 or Grade 2, and have responded quickly to oral metformin. Hyperglycemia has 
not been dose -limit ing since the inst itution of  a standard regimen for early treatment of 
hyperglycemia. 
All patients developing hyperglycemia during the study  shoul d have thei r glucose cl osely 
monitored by  study  staff. The invest igator may choose to continue close monitoring of patients 
who develop Grade 1 hyperglycemia (fast ing glucose >ULN ≤160 m g/dL) or, al ternatively, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 44of 105
Protocol Incorporating Amendment No. 3 02 October 2017
consider init iating treatment with an oral hypoglycemic agent, such as met formin. All pat ients 
with ≥Grade 2 hyperglycemia (fasting glucose >160 mg/dL) must be treated aggressively wit h oral 
hypoglycemic agents and/or insulin as clinically  indicated. The invest igator should consult an 
endocrino logist, if needed, to aid in optimizing the patient’s hyperglycemia treatment plan.
It is recommended that patients be init ially treated with a fast -acting insulin sensit izer such as 
metformin at 500 m g PO QD, and titrate up to a maximum o f 1000 m g PO twi ce daily as needed. 
Concurrent addit ion to m etformin of DPP -4 inhibit ors (eg, sitagliptin or vildaglipt in) and/or 
insulin should also be considered. Oral sulfo nylureas (eg, glipizide or gl yburide) shoul d be used 
with caut ion, due to the higher risk of inducing hypoglycemia in pat ients. The dose of oral 
hypoglycemic agents should be adjusted in pat ients with renal insufficiency . In addi tion, pati ents 
shoul d be encouraged to follow a low carb ohydrate di et once hyperglycemia is first observed.
If any fast ing serum glucose reading performed at the site indicates hyperglycemia (>ULN or 
≥110 mg/dL), the study  staff shoul d first confirm that the patient was fast ing at the time o f blood 
specimen col lection (ie, nothing by  mouth f or at l east 8 hours before collection). To aggressively  
manage the hyperglycemia per standard clinical practice, the fo llowing gui delines ( Table 9.c) are 
provi ded to ai d the invest igator in init iating ant iglycemic therapies.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 45of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Table 9.c Management of Hyperglycemia
Grade Description Treatment MLN0128 Dose Modification
1 FBG>ULN –160 
mg/dL.Continue close monitoring of 
blood glucose. Initi ate o ral 
hypoglycemic agent.None
2 FBG>160 –250 
mg/dL.Initiate oral hypoglycemic agent 
and/o r insulin if not well 
controlled on oral agent.None
≥3 FBG>250 mg/dL. Initiate oral hypoglycemic agent 
and/o r insulin.Hold drug until ≤Grade 2.
Resume MLN0128 based on timing of 
recover y:
≤1 week: resume MLN0128 at same dose.
>1 but ≤2 weeks: resume MLN0128 with 
the dose reduced by 1 level (a).
>2 weeks: d iscontinue MLN0128 treatment 
permanently.
Prevention/Prophylaxis:
Follow fasting serum glucose levels during clinic visits.
Monitor home glucometer test results.
Check HbA1c levels ever y 3 mo nths during therapy.
Recommend lifestyle modifications, as appro priate (balanced diet, limited alcohol consumption, increased physical 
activity ).
Most episodes of Grade 1 and 2 hyperglycemia respond quickly to oral metformin. Early initiation of therapy is 
recommended to prevent higher grade hyperglycemia.
FBG levels ≥150 mg/dL by glucometer should be followed by closer monitoring of serum glucose and possible 
interventio n.
FBG=fasting blood glucose, HbA1c=glycosylated hemoglobin, ULN=upper limit of the normal range.
(a) Refer to Table 9.b.
9.8.2 Management of Hyperlipidemia
Guidance on MLN0128 dose modificat ion for patients with hyperlipidemia is provided in 
Table 9.d.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 46of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Table 9.d M anagement of Hyperlipidemia
Grade Description Treatment MLN0128 Dose Modification
1 Cholesterol:
>ULN -300 mg/dL
Triglycerides:
>150 -300 mg/dLNone None
2 Cholesterol:
>300 -400 mg/dL
Triglycerides:
>300 -500 mg/dLTreat hyperlipidemia according to 
standard guidelines. Triglycerides 
≥500 mg/dL should be treated 
urgently  due to risk of 
pancreatitis.Maintain dose if tolerable. If 
toxicity becomes intolerable, 
interrupt MLN0128 dosing until 
recover y to ≤Grade 1. Resume 
MLN0128 at same dose.
3 Cholesterol:
>400-500 mg/dL
Triglycerides:
>500 -
1000 mg/dLSame as for Grade 2 Hold dose until recover y to 
≤Grade 1, then resume MLN0128 
with the dose reduced by 1 level. 
(a)
4 Cholesterol:
>500 mg/dL
Triglycerides:
>1000 mg/dLSame as for Grade 2 Same as for Grade 3
Prevention/Prophylaxis:
Lifesty le modifications, as appropriate (balanced diet, limited consumption of alcoholic beverages, increased 
physical activity).
ULN=upper limit of the normal range.
(a) Refer to Table 9.b.
9.8.3 Management of Oral Mucositis
Guidance for the prevent ion and management of oral mucosit is is provided in
 Table 9.e. Mucosit is 
prophylaxis is strongly reco mmended for all pat ients while receiving MLN0128.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 47of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Table 9.e Management of Oral Mucositis
Grade Description Treatment MLN0128 Dose Modification
1 Asymptomatic o r mild 
symptoms. Nonalcoholic mouth wash or 0.9% 
salt water rinse; consider topical 
corticosteroids at e arliest signs of 
mucositis.None
2 Moderate pain not interfering 
with oral intake; modified diet 
indicated. Topical analgesic mouth 
treatments; topical corticosteroids; 
initiate antiviral or antifungal 
therapy , if indicated.Maintain dose if tolerable. I f 
toxicity becomes intolerable, 
interrupt MLN0128 dosing until 
recover y to ≤Grade 1. Resume 
MLN0128 at same dose.
3 Severe pain interfering with 
oral intake.Same as for Grade 2; consider 
intralesional corticosteroids.Hold dose until recover y to ≤Grade 
1, then resume MLN0128 with the 
dose reduced by 1 level. (a)
4 Life-threatening 
consequences. Same as for Grade 2; consider 
intralesional corticosteroids.Discontinue MLN0128 treatment 
permanently.
Prevention/Prophylaxis:
Initiate a nonalcoholic mouth wa sh or 0.9% salt water rinses 4 -6 times per day with start of therapy before signs of 
mucositis develop.
Avoid using agents containing hydrogen peroxide, iodine, and thyme derivatives in management of stomatitis as 
they may  worsen mouth ulcers.
(a) Refer t o Table 9.b.
9.8.4 Management of Rash
Patients who develop Grade 4 rash should permanent ly discont inue MLN0128, unless they derive 
clinical benefit, in which case they may  be retreated at a reduced dose level after recov ery to 
Grade 1 severit y. Grade 4 rash is defined as rash acneiform/papulopustular with papules and/or 
pustul es covering any  percent body  surface area, which may  or m ay not be associ ated wi th 
symptoms of pruritus or tenderness, and are associated with exte nsive superinfection wit h IV 
antibiotics indicated; life threatening consequences (NCI CTCAE Version 4.03, effect ive date 
14June 2010 [
32]). 
Guidance for m anagement of rash is provided in
 Table 9.f.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 48of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Table 9.f Management of Rash
Grade Description Treatment MLN0128 Dose Modification
≤2 Macules/papules covering 
≤30% body surface area with or 
without symptoms. Consider treatment with topical 
steroid cream/ointment and/or 
oral antihistamines.None
3 Macules/ papules covering 
30% body surface area with or 
without symptoms. Consider treatment with topical 
steroid cream/ointment, oral 
antihistamines, and/or pulsed 
steroids.Hold until ≤Grade 2; resume 
MLN0128 based on timing of 
recover y:
≤3 weeks: resume MLN012 8 with 
the dose reduced by 1 level. (a)
>3 weeks: discontinue MLN0128 
treatment.
4 Rash acneiform/ 
papulopustular with papules 
and/o r pustules covering any 
percentage of body surface 
area, which may or may not be 
associated with symptoms of 
pruritus or te nderness, and are 
associated with extensive 
superinfection with IV 
antibiotics indicated; life 
threatening consequences.Permanently discontinue MLN0128, 
unless patient is deriving clinical 
benefit, in which case resume at a 
reduced dose level (a) after r ecovery 
to Grade 1 severity.
Prevention/Prophylaxis:
Rash should be managed aggressively. The investigator should consider consulting a dermatologist or other 
specialist, if needed.
A skin biopsy at the site of rash should be considered as soon as possib le after the initial episode.
IV=intravenous.
(a) Refer to Table 9.b.
9.8.5 Management of Nausea and/or Vomiting
Patients who experience Grade 3 nausea or vomiting for >72 hours despite optimal therapy  may 
resum e MLN01
28 at a dose reduced by  1 level .
Guidance for the management of nausea and/or vomit ing is provi ded in Table 9.g.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 49of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Table 9.g Management of Nausea and/or Vomiting
Grade Description Treatment MLN0128 Dose Modification
≤2 Loss of appetite with or 
without decreased oral intake; 
1-5 episodes of vomiting 
within 24 hours.Maximize antiemetic therapy; 
consider IV fluid hydration.None
≥3 Inadequate oral intake; ≥6 
episodes of vomiting within 24 
hours.Maximize antiemetic the rapy; 
initiate tube feeding, IVF, or 
TPN.If experienced for ≤72 hours, hold 
MLN0128 until ≤Grade 1, then 
resume MLN0128 without dose 
modification.
If experienced for >72 hours despite 
optimal therapy, hold MLN0128 until 
≤Grade 1, then resume MLN0128 
with the dose reduced by 1 level. 
Prevention/Prophylaxis:
Prophy lactic use of antiemetic, antinausea, and antidiarrheal medications is encouraged, and these may be 
administered before each dose of MLN0128 as needed throughout the study.
IV=intravenous, IVF=i ntravenous fluids, TPN=total parenteral nutrition.
9.8.6 Management of Noninfectious Pneumonitis
Guidance for the management of pneumo nitis is provided in Table 9.h.
Table 9.h Management of Noninfectious Pneumonitis
Grade Description Treatment MLN0128 Dose Modification
1 Asymptomatic: Radiographic 
findings only.Rule out infection and 
closely  monito r.None
2 Symptomatic:
Not interfering with activities of 
daily  living.Rule out infection and 
consider treatment with 
corticosteroids until 
symptoms improve to 
≤Grade 1.Hold MLN0128 treatment:
When symptoms ≤Grade 1, resume 
MLN0128 with the dose reduced by 
1 level. (a)
If no recover y within 4 weeks, then 
discontinue MLN0128 treatment 
permanently.
3 Symptomatic:
Interfering with activities of daily 
living;
Requires administration of oxygen.Rule out infection and 
consider treatment with 
corticosteroids until 
symptoms improve to 
≤Grade 1.Hold MLN0128 treatment until 
symptoms resolve to ≤Grade 1.
Consider re -initiating MLN0128 
treatment with a dose reduction. (a)
If toxicity recurs at Grade 3, 
discontinue MLN0128 treatment 
permanently.
4 Life-threatening:
Ventilatory support indicated.Rule out infection and 
consider treatmen t with 
corticosteroids.Discontinue MLN0128 treatment 
permanently.
(a) Refer to Table 9.b.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 50of 105
Protocol Incorporating Amendment No. 3 02 October 2017
9.8.7 Management of Other Nonhematologic Toxicities
Guidance on dose adj ustment for pati ents wi th other nonhematol ogic toxi cities, specifically  
fatigue, asthenia, and weakness, is provided in Table 9.i.
Table 9.i Management of Asthenia, Weakness, and Fatigue
Grade Description Treatment Dose Modification
1 Mild; asy mptomatic or mild 
symptoms; clinical or diagnostic 
observations only; intervention 
not indicated.Initiate appropriate medical 
therapy  and monitor.If tolerable, then no adjustment is 
required.
2 Moderate; minimal, local or 
noninvasive intervention 
indicated.Initiate appropriate medical 
therapy  and monitor.If tolerable, no adjustment required.
If toxicity becomes intolerable, hold 
MLN0128 treatment until symptoms 
resolve to ≤Grade 1, then re -initiate at 
same dose. 
≥ 3 Severe or medically significant 
but not immediately 
life-threatening; hospitalization 
or prolongation of 
hospitalization indica ted.Hold MLN0128 treatment until 
symptoms resolve to ≤Grade 1. 
Re-initiate MLN0128 treatment with 
a dose reduction. (a)
(a) Refer to Table 9.b.
9.9 Blinding and Unblinding
This is an open -label study .
9.10 Description o f Investigational Agents
MLN0128 will be supplied as capsules for oral administration. MLN0128 is available in 3 dose 
strengths (1, 3, and 5 mg of MLN0128). The capsules contain milled drug substance , 
microcrystalline cellulose, and magnesium stearate. All 3 dose strengths are formulated into size 2 
hard-gelat in capsules, and each dose strength is differentiated by co lor:
1mg MLN0128 capsules: white opaque.
3mg MLN0128 capsules: Swedish orange opaque.
5mg MLN0128 capsules: gray  opaque.
Fulvestrant is a c ommercially  available drug supplied as a solut ion for IM injection and will be 
procured or distributed according to the Pharmacy Manual. Please refer to the mo st recent USPI or 
SmPC for more informati on regarding fulvestrant.
9.11 Preparation, Reconstitution, a nd Dispensation
MLN0128 will be provided in 60 cc high -densi ty polyethylene (HDPE) bottles wit h 
polypropylene, child -resistant caps and induction seal. MLN0128 will be dispensed with dosing 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 51of 105
Protocol Incorporating Amendment No. 3 02 October 2017
instructi ons for home use, including the requirement that capsules are stored in their original 
containers and that capsules be swallowed who le and not opened, chewed, or manipulated in any 
way. Materi als provi ded by  the sponsor shoul d be di spensed to pati ents wi th clear administration 
instructi ons fro m the investigator.
MLN0128 is an ant icancer drug and, as with other potentially toxic co mpounds, caution should be 
exercised when handling MLN0128 capsules.
Refer to the fulvestrant USPI or SmPC for details regarding the preparation, reconstitution, and 
dispensat ion of fulv estrant.
9.12 Packaging and Labeling
MLN0128 will be provided by  Millennium and will be handled at the invest igative site as 
open -label materi al. MLN0128 capsules are packaged in 60 cc HDPE bottles with polypropylene, 
child -resistant caps and an induct ion seal. For all 3 dose strengths, each bottle contains 30 capsules 
and will have a label containing pertinent study information, country -specific requirements, and a 
cauti on statem ent.
While the patient is enrolled in the study , fulvestrant m ay be supplied eit herby the site fro m 
commercial sources (US sites) or provided by Millennium (ex -US si tes). When provi ded by  
Millennium, fulvestrant will be appropriately labeled in compliance wit h local and regi onal 
regul ations.
9.13 Storage, Handling, and Accountability
Upon re ceipt at the invest igative site, MLN0128 should be stored in the original bottles unt il use 
and stored at room temperature from 15 C to 30C (59F to 86 F). All temperature excursio ns will 
be reported to the sponsor for assessment and authorizat ion for con tinued use. All invest igational 
supplies must be stored in a secure area with controlled access and will be stored in original 
packaging. All MLN0128 should be used before the retest expiry date.
Refer to the current fulvestrant USPI or SmPC for details r
egarding the storage and handling of 
fulvestrant.
A drug dispensing log, including records of drug received fro m the sponsor and drug dispensed to 
the pati ents, will be provided and kept at the study  site. Storage area temperature conditions must 
be monitored and recorded daily. A daily temperature log will also be kept at the study  site.
Because MLN0128 is an investigational agent, it should be handled wit h due care. In case of 
contact wi th broken capsules, raising dust should be avo ided during the clean -up operati on. The 
product may be harmful if inhaled, ingested, or absorbed through the skin. Gloves and protective 
clothing shoul d be worn during the clean -up operatio n. The area should be vent
ilated and the spill 
site washed after m aterial pick -up is complete. The spilled material should be disposed of as 
hazardous medical waste in co mpliance with federal, state, and local regulat ions. In case of contact 
with the powder (eg, from a broken capsule), the skin should be washed immediately wit h soap 
and copi ousamounts of water for at least 15 minutes. In case of contact with the eyes, copious 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 52of 105
Protocol Incorporating Amendment No. 3 02 October 2017
amounts of water should be used to flush the ey es for at l east 15 minutes. Medi cal personnel 
shoul d be notified.
Patients will  receive instructi ons for hom e storage and ad ministrati on of  MLN0128.
Patients will  be instructed to return any  unused study  drug in the ori ginal packaging alo ng with 
their com pleted pati ent dosing di ary at the appropriate visits per the Schedule ofEvents .
Please refe r to the Invest igator Site File for additional instructions.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 53of 105
Protocol Incorporating Amendment No. 3 02 October 2017
10.0 STUDY CONDUCT
This tri al will be conducted in com pliance wi th the protocol , Good Clinical Pract ice (GCP), 
applicable regulatory  requi rements, and Internat ional Conference on Harmonisat ion (ICH) 
guidelines.
10.1 Study Personnel and Organizations
The contact informat ion for the proj ect clinician for this study , the central  laboratory  and any 
additional clinical  laboratories, the coordinat ing investigator for each member state/country  
(where applicable), the IRT provider, and the study  monitoring team may be found in the 
Invest igator Site File. A full list of invest igators is available in the sponsor’s invest igator database.
10.2 Arrangements for Recruitment of Patients
Recrui tment and enro llment strategies for this study may  include recrui tment from the 
investigator’s local practice or referrals from other physicians. If advert isements become part of 
the recruit ment strategy , they  will be reviewed by  the inst itutional review board 
(IRB)/independent ethics co mmittee (IEC).
10.3 Treatment Group Assignments
Patient eligibilit y will be established before rando mizat ion into the study. Patient eligibilit y will be 
confirmed by the sponsor’s project clinician (or designee) before rando mizat ion by the 
investigator into the st udy. A centralized rando mization IRT will be used for treatment group 
assignment.
Enrollment will be managed via the IRT to ensure that approximately 40% of enro lled patients 
have previously received CDK4/6 inhibitors in combinat ion with an AI. Enrollment of 
non
-CDK4/6 pretreated patients may  be stopped in the case that 60% or greater of enro llment has 
occurred with only  non-CDK4/6 pretreated patients.
Patients who m eet the eligibilit y criteria will be stratified according to the presence or absence o f 
visceral metastasi s, previous sensit ivity to hormonal therapy , and previ ous exposure to CDK4/6 
inhibitors. Visceral metastasis is defined as all lesions not included in the fo llowing list: breast, 
skin, subcutaneous tissue, lymph node, or bone. Previous sensit ivity to horm onal therapy  is 
defined as at least 24 months of endocrine therapy before recurrence in the adjuvant setting (ie, in 
patients who have not received previous endocrine therapy in the metastatic setting) or a response 
or stabilizat ion for at lea st 24 weeks of the most recent endocrine therapy for advanced/metastatic 
disease. Pati ents will  be randomized 1:1:1 to 1 of 3 treatment arms (51 patients per arm):
Arm A: Single -agent fulvestrant.
Arm B: Co mbinat ion of fulvestrant+daily  MLN0128.
Arm C: Co mbinat ion of fulvestrant+weekly MLN0128.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 54of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Patients in the single -agent fulvestrant arm (Arm A) who have PD may be allowed to receive 
crossover treatm ent with the combinat ion of fulvestrant+MLN0128, as detailed in Sect ion 7.1.4 . A 
centralized rando mizat ion IRT will be used to randomize crossover patients in a 1:1 ratio to either 
fulvestrant+daily MLN0128 or fulvestrant+weekly MLN0128. Patients who discont inue 
fulvestrant in eit her of the combinat ion treatment arms ( Arm B or Arm  C) m ay be eligible to 
continue receiving MLN0128 at their current dose as described in Sect ion 7.1.5 . If MLN0128 is 
discontinued for a pati ent in either of the combinatio n treatment arms (Arm B or A rm C), the 
patient will co mplete the EOT Visit and be fo llowed for PFS/OS as detailed in Section 10.7.
10.4 Study Procedures
Patients will  be evaluated at scheduled visits over the fo llowing study  periods: Screening,
Treatment, EOT, and PFS/OS Follow -Up. Unless otherwise noted, evaluat ions during the 
Screening period are to be conducted within 28 days before administration of the first dose of 
study  drug. Eval uations during the Treatment Period must occur before study drug administration 
on that day . Tests and procedures should be performed on schedule for all visits but occasional 
changes are allowable (±2 days) for ho lidays, vacatio ns, and other administrative reasons, starting 
after the com pletion of Cycle 2 Day  1.
All EOT evaluat ions should occur within 30 to 40 days after the last dose of study drug, or before 
the start of subsequent antineoplastic therapy  (or crossover treatment if applicable; see 
Secti on7.1) if that o ccurs earlier than 30 days after the last dose.
Refer to the
 Schedule ofEvents for timing of assessments. Addit ional details are provided as 
necessary  in the secti ons that follow.
10.4.1 Informed Consent
Each patient must provide written inform ed consent before any  study -requi red procedures are 
conducted, unless those procedures are performed as part of the patient’s standard care.
10.4.2 Patient Demographics
The date of birth, race, ethnicit y, and sex of the patient are to be recorded du ring Screening.
10.4.3 Medical History
During Screening Period, a complete medical history  will be com piled for each patient. The 
history  will emphasize the background and progress of the patient’s malignancy  and include a 
descript ion of prior therapies for it. 
10.4.4 Enrollment
Enrollment is defined as being rando mized to a treatment arm .
Enrollment will be managed via the IRT to ensure that approximately 40% of enro lled patients 
previously received CDK4/6 inhibitors in co mbination with an AI.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 55of 105
Protocol Incorporating Amendment No. 3 02 October 2017
10.4.5 Patient Height and Weight
Height will be measured only during Screening. Body  weight will be m easured at the visits 
specified in the Schedule ofEvents .
10.4.6 Physical Examination
A physical examinat ion will be completed per standard of care at the times specified in the 
Schedule ofEvents .
10.4.7 Vital Signs
Vital sign m easurements, including diastolic and systolic blood pressure, heart rate, and 
temperature will be measured at the visits specified in the Schedule ofEvents .
10.4.8 ECOG Performance Status
Perform ance status will be assessed according to the ECOG scale (see Appendix D) at the time 
points specified in the Schedule ofEvents .
10.4.9 ECG
A single, 12- lead ECG will be performed predose on Day  1 of every  cycle and during the EOT 
Visit. When the timing of an ECG coincides with blood samples, the ECG should be completed 
first. Addi tional ECGs may  be obtained as clinically  indicated.
10.4.10 Disease A ssessment
10.4.10.1 CT Scan or MRI
Patients will  undergo CT scan (wi th contrast) as appropriate to monitor and assess PD, using 
RECIST guidelines (Versio n1.1), where measureable disease is defined as at least 1 extra -osseous 
lesion that can be accurately measured i n at l east 1 dimensio n [1]. An MRI may be performed for 
patients who are allergic to CT contrast or for patients with specific disease sites that cannot be 
adequately  imaged by  CT scan. Anatomical measurements (summed across target lesio ns) will be 
collected at Baseline and at ea ch subsequent evaluation using an imaging modalit y consistent with 
that used at Screening. Objective assessments will be performed at each time point specified in the 
Schedule ofEvents .
 When possible, the same qualified phy sician will interpret results to reduce 
variabilit y.
In the absence of measurable disease at Baseline, the fo llowing will be considered PD among 
patients wi th bone -only disease:
The appearance of 1 or more new lyt ic lesio ns in bone.
The appearance of any  extra-osseous l esions.
Unequivocal progression of exist ing bone lesio ns.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 56of 105
Protocol Incorporating Amendment No. 3 02 October 2017
All images will be collected and qualit y controlled by a sponsor -specified central imaging vendor. 
Radiographic images will be maintained at the site, and test resul ts and physicians’ findings will be 
filed in patient source documents. The sponsor may request electronic images for those patients 
who dem onstrate a response.
10.4.10.2 Bone Scan
A bone scan will be required for all pat ients during Screening (within 21 days before the first dose 
of study drug), and thereafter at the discretion of the invest igator to monitor representative areas.
10.4.10.3 Health -related Quality of Life Assessments
The HRQL instruments, EORTC QLQ -C30 and EORTC QLQ -BR23 , will  be administered as 
specified in the Schedule ofEvents , and they  must be com pleted before other assessments are 
perform ed or study  drug i s administered.
The EORTC QLQ -C30 incorporates 5 functional scales (physical funct ioning, role functioning, 
emotional funct ioning, cognit ive funct ioning, and social functioning); 1 global healt h status scale; 
3 symptom scales (fatigue, nausea and vo miting, and pain); and 6 single items (dyspnea, insomnia, 
appeti te loss, consti pation, di arrhea, and financial difficult ies). (See Appendix H.) The time recall 
period for this instrument is 1 week (the past week). The EORTC QLQ -C30 is a reliable and valid 
measure of HRQL in pat ients with cancer [34]. The instrument consists of a brief (30 -item) 
questionnaire that has been validated and used in many countries.
The EORTC QLQ -BR23 is an instrument specific to breast cancer that was designed to be used in 
conjunction with the EORTC QLQ -C30. The questio nnaire comprises 23 items on issues relevant  
to patients with breast cancer that are not, or not sufficient ly, covered by the core questionnaire. 
The EORTC QLQ -BR23 instrument incorporates 2 funct ional scales (body  image and se xual 
funct ioning), 3 symptom scales (arm symptoms, breast symptoms, and systemic side effects), and 
single items related to sexual enjo yment, di stress by  hair loss, and future perspecti ve (see 
Appendix I)
. The recall period for this instrument is 1 week (the past week), except for items 
related to sexual funct ion (recall period of 4 weeks). The instrument has been validated in many 
languages and among pat ients varying in disease stage and treatment modalit y [35].
10.4.11 Concomitant Medications and Procedures
Medicat ions used by the patient and therapeutic procedures completed by the patient from the first 
dose of study drug through 30 days after the last dose of study drug will be recorded on the eCRF. 
See Secti on
 9.5and Section 9.6for a list of medications and therapies that are prohibited and/or 
allowed during the study .
10.4.12 AEs
Moni toring of AEs, serious and nonserious, will be conducted throughout the study as specified in 
the Schedule ofEvents . Refer to Section 11.0 for details regarding definit ions, documentation, and 
reporting of pretreatment events (PTEs), AEs, and SAEs.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 57of 105
Protocol Incorporating Amendment No. 3 02 October 2017
10.4.13 Patient Diary Instruction and Review
At the beginning of each cycle, patients in Arms B and C will receive a diary in which to record 
their dosing and fast ing blood glucose (FBG) testing results. The study center staff will check th e 
patient’s diary  versus the pati ent’s supply  of remaining study  drug at each study  visit to ensure 
compliance wi th dosing. Patients who are not compliant with the dosing schedule may  be 
withdrawn from  the study .
10.4.14 Clinical Laboratory Evaluations
Clinical la boratory  evaluat ions will be performed locally.
Blood specimens for analysis of the clinical chemistry , hematol ogy, and coagul ation parameters 
shown in Table 10.a and urine specimens for analysis of the parameters shown in  Table 10.b will 
be obtained as specified in the
 Schedule ofEvents .
Table 10.a Clinical Chemistry, Hematology, and Coagula tion Tests
Hematology and Coagulation Chemistry
Hematocrit (Hct)
Hemoglobin (Hgb)
Leukocytes with differential
Neutrophils (ANC)
Platelets (count)
Activated partial thromboplastin time 
(aPTT)
Prothrombin time/international 
normalized ratio (PT/INR)Albumi n
Alkaline phosphatase (ALP)
ALT
Amylase
AST
Bilirubin (total and direct) (b)
Blood urea nitrogen (BUN) or Urea
Calcium (total)
Carbon dioxide (CO 2) or bicarbonate
Chloride
CreatinineGamma glutamyl transferase (GGT)
Glucose
Glycosylated hemoglobin (HbA1c) (a)
Lactate dehydrogenase (LDH)
Magnesium
Phosphate
Potassium
Protein (total)
Sodium
Urate
(a) Assessed only at the time points specified in the Schedule ofEvents .
(b) Direct bilirubin will be measured only if total bilir ubin is altered.
Table 10.b Clinical Urinalysis Tests
Urinalysis (a)
Bilirubin
Color
Glucose
Ketones
Leukocytes
NitriteOccult blood
pH
Protein
Specific gravity
Turbidity
Urobilinogen
(a) The use of test strips is permitted.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 58of 105
Protocol Incorporating Amendment No. 3 02 October 2017
For Screening, creatinine clearance must be ≥40 mL/min based eit her on Cockroft -Gault estimate 
or based on a 12 -or 24 -hour urine co llection.
Prospective mo nitoring for hy perlipidemia will be managed through fast ing lipid testing. 
Sampling for the fast ing lipid profile ( Table 10.c) will be obtained at the times specified in the 
Schedule ofEvents .
Table 10.c Fasting Lipid Profile
Fasting Lipid Profi le
Cholesterol (total)
TriglyceridesHigh -density lipoprotein cholesterol
Low-density  lipoprotein cholesterol
Fasting serum glucose will be measured in the clinic at the time points specified in the 
Schedule ofEvents . Patients are requi red to fast overnight (nothing except water and/or 
medicat ions after midnight or for a minimum of 8 hours before the assessment) for each of these 
measurements. For patients receiving single -agent fulvestrant in Arm A or fulvestrant+MLN0128
QW in Arm C, the fasting serum glucose may  be assessed as part of the predose chemistry  panel . 
After fasted sampling is complete, patients receiving fulvestrant+MLN0128 QW in Arm C should 
consume a light meal prior to dosing (Section 9.1). For pati ents receiving fulvestrant+MLN0128 
QD in Arm B, a separate sample must be taken approximately  2 hours after study  drug 
administration, with patients continuing to fast until that sample is taken.
In-home g lucose monito ring is not required on days when fast ing glucose is measured in the clinic.
10.4.15 In-Home Daily FBG Monitoring (Combination Arms Only)
In addit ion to obtaining fast ing serum glucose levels at the clinic visits as outlined in the 
Schedule ofEvents , all patients in the co mbination fulvestrant+MLN0128 treatment arms (Arm B 
and Ar m C) will be given a gluco meter to monitor their daily FBG levels at home. The level should 
be co llected daily, predose on dosing days, and at approximately the same t ime each day. Before 
checking their blood glucose levels, patients should fast overnight (nothing except water and/or 
medicat ions after midnight or for a minimum of 8 hours before the assessment). After fasted 
testing is co mplete, patients in Ar m C shoul d consum e a light m eal prior to MLN0128 dosing 
(Secti on9.1).
On Cycle 1 Day 1, the patient will be provided an in -home gluco meter. Patients will be trained on 
proper use of the gluco meter and instructe d to collect a daily fast ing glucose level every morning 
(predose on dosing days), starting on Cycle 1 Day  2. Pati ents will  be instructed to bring the 
glucometer with them to each study visit so that the data collected can be reviewed and recorded in 
the source docum ents. Invest igators will be responsible for reviewing the ho me glucose 
monitoring l ogs f or hy perglycemia.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 59 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
The patient will be instructed to contact the site immediately if the value is abnormal 
(ie,#150 mg/dL) for further instructions on the management of their hyperglycemia. 
Hyperglycemia observed during home glucose monitoring should be confirmed in the clinic.
If no irregularities in the FBG level are observed during a minimum of 2 consecutive months, then 
the frequency of in-home FBG testing can be re duced to a minimum frequency of once weekly, 
depending on the investigator’s judgement and approval. Patients will continue to notify the 
investigator of FBG levels that exceed 150 mg/dL and, if blood glucose levels are not well 
controlled, or if the patient requires either ora l hypoglycemic agents or insulin to control blood 
glucose levels, then the frequency of in-home testing of FBG levels will be reinstated to daily.
See also Section  9.8.1.
10.4.16Biomar ker Measurements in Blood
10.4.18Banked Tumor Sp ecimen MeasurementsCCI
CCICCI
Property of Take88BankBan
roperty of Tato the Applicable Terms of Uses, then then
weeklyweekly
ify the fy the
not wellot we
o controo contr
einstatednstate
Non-Commercial Use Only and Subject to rN o
keda: For N
MLN0128 (TAK-228)
Study No. C31006 Page 60 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
10.4.19PK Measurements  (Combination Arms Only)
Blood sampling to characterize the PK of MLN 0128 will be performed for patients randomized to 
the combination fulvestrant+MLN0128 treatment arms (Arm B and Arm C, including patients 
who receive crossover treatment), at the times indicated in the  Schedule of Events.  When the 
timing of a PK blood sample coincides with vital si gn or ECG measurements, the vital sign or ECG 
measurement should be obtained before the PK blood sample. Details on the collection, storage, 
processing, handling, and shipping of PK samples are in the  Central Laboratory Manual.
PK data for MLN0128 will be combined with similar data from other studies for future population 
PK analysis. The results of the population PK analysis will not be presented in the clinical study 
report and may be presented in a separate population PK analysis report at a later time. 
10.5 Completion of Study Treatment
Patients will be considered to have completed treatment if they discontinue study drug for any of 
the reasons outlined in Section  10.7.
10.6 Completion of Study
Patients will be considered to have completed the study if they withdraw from the study for any of 
the reasons outlined in Section  10.8.
10.7 Discontinuation of Treatment With Study Drug 
Treatment with study drug may be discont inued for any of the following reasons:
!AE.
!Protocol deviation.
!PD.
!Symptomatic deterioration.
!Study terminated by sponsor.
!Withdrawal by patient.
!Lost to follow-up.CCI
CCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicd for patfor pa
Arm CArm C
heduleedule
measuremeasu
ple. Detae. De
the the 
r data frdata f
alysis wlysis w
ulatlation Pion P
t
ompletemple
7.
y
ed to hato h
n SectSectio
inuationnuati
with studwith stu
ProtocoProtoc
!!PDPD
!!se
licable Terms of Use
SuCCICC
MLN0128 (TAK -228)
Study No. C31006 Page 61of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Other (eg , investigator’s decisio n to init iate a different therapy , pati ent noncom pliance wi th 
study  requi rements).
Patients m ust discont inue study  drug if they  experience PD or unacceptable toxicit y.
Once study  drug has been discont inued, all study  procedures outl ined for the EOT Visit will be 
completed as specified in the Schedule ofEvents . The primary  reason for study  drug 
discontinuat ion will  be recorded on the eCRF.
Note that some patients may discont inue study drug for reasons other than PD. These pat ients will 
remain in the study  for post -treatm ent assessments as outlined in the Schedule ofEvents and 
Secti on 10.10 .
10.8 Withdrawal of Patients From Study
A patient may be wi thdrawn from  the study  for any  of the f ollowing reasons:
Lost to follow -up.
Study  terminated by  sponsor.
Withdrawal by pat ient.
Death.
Other.
The consequence of study  withdrawal  is that no new informat ion will be collected from the 
withdrawn pati ent and added to the exist ing data or any database. Data on survival may be 
obtained fro m publically available databases and sources.
10.9 Study Compliance
Study  drug will be administered or dispensed only to eligible pat ients under the supervisio n of the 
investigator or ident ified subinvest igator(s). The appropriate study personnel will maintain records 
of study  drug recei pt and dispensing.
Patients will  receive a sufficient quant ity of MLN0128 for each treatment cy cle and a di ary in 
which to record their dosing. The study center staff will check the pat ient’s dosing diary versus the 
patient’s supply  of remaining study
 drug at each study  visit to ensure proper com pliance wi th 
dosing. Patients who are not compliant with the dosing schedule may be withdrawn from the study.
10.10 Post-Treatment Follow -up Assessments (Progression- Free Survival and Overall 
Survival)
After the EOT Visit (or, for crossover patients, after their second and final EOT Visit), patients 
will be fo llowed f or PFS and OS. Patients who disconti nue study  treatm ent for reasons other than 
PD will cont inue to have PFS fo llow-up visit s every 2 mo nths (±1 week) for the first 6 months 
after the EOT Visit, then every 3 mo nths (±1 week) until PD or start of another ant icancer therap y 
for treatm ent of dis ease under study , whichever occurs first. After PD or the start of another 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 62of 105
Protocol Incorporating Amendment No. 3 02 October 2017
anticancer therapy, patients will be fo llowed for OS every 6 mo nths (±1 week) . OS fo llow-up will 
continue until approximately  20 m onths after the first patient is randomized, or whe n the l ast 
patient discont inues study treatment. Survivor info rmation and death details may be co llected by 
methods that include, but are not limited to, telephone, e -mail, mail, or retrieved fro m online or 
other databases (eg, Social Securit y indexes). In addit ion, the start of any other anticancer therap y 
for treatm ent of disease under study  will be collected. Refer to the Schedule ofEvents for 
appropriate assessments during posttreatment follo w-up.
NOTE: Any SAEs occurrin g after the EOT Visit that are considered related to study drug must be 
reported to Takeda Global Pharmacovigilance department or designee. This includes deaths that 
the invest igator considers related to study  drug that occur during the posttreatment fo llow-up. 
Refer to Section 11.0 for details regarding definit ions, docum entati on, and reporti ng of SAEs.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 63of 105
Protocol Incorporating Amendment No. 3 02 October 2017
11.0 ADVERSE EVENTS
11.1 Definitions
11.1.1 PTE Definition
A PTE i s any  untoward m edical occurrence in a patient or subject who has signed informed 
consent to participate in a study  before administrati on of any study  medicat ion; it does not 
necessarily have to have a causal relationship with study  participati on.
11.1.2 AE Definition
AE means any untoward medical occurrence in a patient o r subject administered a pharmaceut ical 
product; the untoward medical occurrence does not necessarily have a causal relat ionship wit h this 
treatm ent. An AE can therefore be any unfavorable and unintended sign (including an abnormal 
laboratory  finding), sym ptom , or disease tem porally  associ ated wi th the use of a m edicinal 
(invest igational) product whether or not it is related to the medicinal product. This includes any 
newly occurring event or a previous condit ion that has increased in severit y or frequency since the 
administration of study  drug.
An abnormal laboratory  value will not be assessed as an AE unless that value leads to 
discontinuat ion or delay in treatment, dose modification, therapeutic intervent ion, or is considered 
by the investigator to be a c linically significant change fro m Baseline.
11.1.3 SAE Definition
SAE m eans any untoward medical occurrence that at any  dose:
Results in death.
Is life-threatening (refers to an AE in which the patient was at risk of death at the time of the 
event. It does not re fer to an event which hypothetically might have caused death if it were 
more severe).
Requi res inpat ienthospitalization or prolongation of an existing hospitalization (see 
clarificati onin the paragraph in Sect ion 11.2 on planned hospitalizat ions).
Results in persistent or significant disability or incapacity . (Disabilit y is defined as a 
substant ial disrupt ion of a person’s abilit y to conduct normal life functions.)
Is a congenital anomaly/birth defect .
Is a medically important event . This refers to an AE that may  not resul t in death, be 
immediately  life threatening, or require hospitalization, but may be considered serious when, 
based on appropriate medical judgment, may  jeopardize the pati ent, requi re medical or 
surgi cal interventi on to prevent 1 of the outcomes listed above, or involves suspected 
transmissio n via a medicinal product of an infect ious agent. Examples of such medical events 
include allergic bronchospasm requiri ng intensive treatment in an emergency room or at home, 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 64of 105
Protocol Incorporating Amendment No. 3 02 October 2017
blood dyscrasias or convulsio ns that do not result in inpatient hospitalizat ion, or the 
development of drug dependency  or drug abuse; any  organism , virus, or infecti ous parti cle 
(eg,prion protein tra nsmitt ing transmissible spongiform encephalopathy), pathogenic or 
nonpathogenic, is considered an infect ious agent.
In thi s study , intensi ty for each AE, including any  lab abnormalit y, will be determined using the 
NCI CTCAE, Version 4.03, effective date 14 June 2010 [32]. Clarificati on shoul d be m ade 
between an SAE and an AE that is considered severe in intensit y (Grade 3 or 4), because the terms 
serious and severe are NOT synonymous. The general term severe is often used to describe the 
intensity (severi ty) of a specific event; the event itself, ho wever, m ay be of  relatively minor 
medical significance (such as a Grade 3 headache). This is NOT the same as serious , which is 
based on patient/event outcome or action criteria described above, and is usually associated with 
events that pose a threat to a patient’s life or abilit y to functi on. A severe AE (Grade 3 or 4) does 
not necessarily need to be considered serious. For example, a white blood cell count of 1000/mm3
to less than 2000 i s considered Grade 3 (severe) but may not be considered serious. Seri ousness 
(not intensit y) serves as a guide for defining regulatory  reporti ng obligat ions.
11.2 Procedures for Recording and Reporting AEs and SAEs
All AEs spontaneously reported by  the pati ent and/or in response to an open question fro m study  
personnel or reveal ed by observation, physical examinat ion, or other diagnostic procedures will be 
recorded on the appropriate page of the eCRF (see Section
 11.3 for the period of observat ion). Any 
clinically relevant deterioratio n in laboratory assessments or other clinical finding is considered an 
AE. When possible, signs and symptoms indicating a commo n underlying patho logy shoul d be 
noted as 1 comprehensive event.
Regardless of causality, SAEs and serious PTEs (as defined in Se ction 11.1) must be reported (see 
Secti on 11.3 for the peri od of  observati on) by  the investi gator to the Takeda Global 
Pharmacovigilance department or designee (conta ct information provided below). This should be 
done by faxing the SAE Form within 24 hours after beco ming aware of the event. The SAE Form, 
created specifically by  Takeda, will be provi ded to each clinical study  site. A sample of the SAE 
Form  may be found in the Invest igator Site File. Follow -up informat ion on the SAE or serious PTE 
may be requested by Takeda. SAE report informat ion must be consistent with the data provided on 
the eCRF.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 65 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Planned hospital admissions or surgical procedures for an illness or disease that existed before the 
first dose of study drug are not to be considered AEs unless the condition deteriorated in an 
unexpected manner during the trial (eg, surgery wa s performed earlier or later than planned).
For both serious and nonserious AEs, the investigator must determine both the intensity of the 
event and the relationship of the event to study drug administration. For serious PTEs, the 
investigator must determine both the intensity of the event and the relationship of the event to 
study procedures.
Intensity for each AE, in cluding any la boratory  abnorm ality, w ill be determined using the 
NCI CTCAE, Version 4.03, effective date 14 June 2010 [32].
Causality (relationship) to study drug administration will be determined by the investigator 
responding yes (Related) or no (Not Related) to this question: Is there a reasonable possibility that 
the AE is associated with the study drug?
11.3 Monitoring of AEs and Period of Observation
AEs, both nonserious and serious, will be monitored throughout the study as follows:
!AEs will be reported from first dose of study  drug through 30 days after administration of the 
last dose of study drug and recorded on the eCRFs.
!Serious PTEs will be reported to the Takeda Global Pharmacovigilance department or 
designee from the time of the signing of the i nformed consent form up to first dose of study 
drug, but will not be recorded on the eCRF.
!Related and unrelated SAEs will be reported to the Takeda Global Pharmacovigilance 
department or designee from the first dose of study drug through 30 days after administration
of the last dose of study drug and recorded on the eCRF. After this period, only related SAEs 
must be reported to the Takeda Global Pharmacovigilance department or designee. SAEs 
should be monitored until they are resolved or ar e clearly determined to be due to a patient’s 
stable or chronic condition or intercurrent illness(es).PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Adiseasediseas
onditondit ioi
d earlied earl
ust detert dete
dministrminis
e event even
oryryabnoaby
e 14 Jun14 Ju
ug adming adm
ot RelateRela
udydydrudruyy
Es and Ps and
and serind s
eported ported
f studystudy dy
s PTEs wPTEs
gnee frognee fr
drug, butrug, bu
RelaReof Usefofo
dApplicable Terms of
MLN0128 (TAK-228)
Study No. C31006 Page 66 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
11.4 Procedures for Reporting Drug Exposure During Pregnancy and Birth Events
Reporting procedures for pregnancy and birth events are not applicable for this study as enrollment 
is restricted to postmenopausal women only.
11.5 Procedures for Reporting Product Complaints
A product complaint is a verbal, written, or electronic expression that implies dissatisfaction 
regarding the identity, strength, purity, quality , or stability of  a drug product. Individuals who 
identify a potential product complaint situation should immediately contact the Medical 
Information Call Center  / and report the complaint. The contact 
information is as follows: 
Medical Information Call Center:Phone:
Fax:
E-mail:
Hours:
Whenever possible, the associated product should be maintained in accordance with the label 
instructions pending further guidance from a Millennium Quality representative.
Product complaints in and of themselves are not AEs. If a product complaint results in an SAE, an 
SAE form should be completed and sent to  (refer to Section 11.2) .
11.6 Safety Reporting to Investigators, IRBs or IECs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse reactions 
(SUSARs) and any other applicable SAEs to regulatory authorities, including the European 
Medicines Agency, investigators and IRBs or IECs, as applicable, in accordance with national 
regulations in the countries where the study is conducted. Relative to the first awareness of the 
event by/or further provision to the sponsor or sponsor’s designee, SUSARs will be submitted to 
the regulatory authorities as an expedited report within 7 calendar days for fatal and 
life-threatening events and 15 calendar days for other serious events, unless otherwise required by 
national regulations. The sponsor will also prepare an expedited report for other safety issues 
where these might materially alter the current benefit-risk assessment of an investigational 
medicinal product or that would be sufficient to consider changes in the investigational medicinal 
product’s administration or in the overall conduct of the trial. The investigational site also will 
forward a copy of all expedited reports to his or her IRB or IEC in accordance with national 
regulations.PPDPPD
PPD
Property of Takeda: For Non-Commercial Use Only ahould beuld b
m a Milla M
ves are nes are 
d sent tosent t
Investignvesti
nsible fnsible 
her applir app
investnvest ig
e countre coun
rther proher p
oryryauthauyy
atening atening
nal regunal reg
here thesere th
medicinmedic
prodproApplicable Terms of Usefactacioion
viduals wduals
MediMedi ca
plaint. laint. T
fofand Subject to the A
MLN0128 (TAK -228)
Study No. C31006 Page 67of 105
Protocol Incorporating Amendment No. 3 02 October 2017
12.0 STUDY- SPECIFIC COMMITTEES
A Steering Co mmittee, comprising Takeda clinical research and bio statist ics representatives, 
study  site investi gators, and m edical consultants from GEICAM will be responsible for 
performing the safet y and tol erabili ty assessmen t for the first 6 evaluable patients treated in Arm 
C. The purpose of this assessment is to confirm the weekly dose of 30 mg MLN0128 in 
combinat ion with fulvestrant (see Section 7.1.2 for details). After this as sessment is completed, the 
Steering Committee will be available to meet on an ad hoc basis to review study data as necessary. 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 68of 105
Protocol Incorporating Amendment No. 3 02 October 2017
13.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
If selected for coding, AEs, PTEs, medical history, and concurrent condit ions will be coded using 
the Medi cal Dict ionary for Regulatory  Activities (MedDRA). Drugs will be coded using the 
World Heal th Organizat ion (WHO) Drug Dict ionary.
13.1 Electronic Case Repo rt Forms 
Com pleted eCRFs are required for each randomized subject. 
The sponsor or its designee will supply invest igative sites with access to eCRFs and will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study  to the sponsor, contract research 
organi zation partners, and regulatory  authori ties. Investi gative si tes m ust com plete eCRFs in 
English.
After complet ion of the entry process, computer lo gic checks will be run to identify items, such as 
inconsistent dates, missing data, and questionable values. Queries may be issued by Takeda 
personnel (or designees) and will be answered by the site.
Any change of, modificat ion of, or addit ion to the data on the eCRFs should be made by the 
investigator or appropriate site personnel . Corrections to eCRFs are recorded in an audit trail that 
captures the old informat ion, the new information, ident ificat ion of the person making the 
correcti on, the date the corr ection was made, and the reason for change.
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriate eCRFs as indicated. Furthermore, the principal invest igator must retain 
full responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs.
eCRFs will be reviewed for completeness and acceptabilit y at the study  site during peri odic visi ts 
by study  monitors. The sponsor or i ts designee will be permitted to review the subject’s me dical 
and hospital records pertinent to the study to ensure accuracy of the eCRFs. The completed eCRFs 
are the sole property  of the sponsor and should not be made available in any form to third parties, 
except for authorized representatives of appropriate governmental healt h or regulatory authorities, 
without wri tten permissio n from the sponsor.
13.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 13.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copy  of eCRFs, incl uding the audi t trail, and detailed records of drug disposit ion to 
enable evaluat ions or audits from regulato ry authori ties, and the sponsor or its designees. Any  
source documentation printed on degradable thermal sensit ive paper should be photocopied by the 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 69of 105
Protocol Incorporating Amendment No. 3 02 October 2017
site and filed wit h the original in the subject’s chart to ensure long term legibilit y. Furtherm ore, 
ICH E 6 Section 4.9.5 requires the invest igator to retain essent ial documents specified in ICH E6 
Secti on8 until at least 2 years after the last approval o f a marketing applicat ion for a specified drug 
indicat ion being investigated or, if an applicat ion is not approved, until at least 2 years after the 
investigat ion is discont inued and regulatory  authorit ies are notified. In addit ion, ICH E6 
Secti on4.9.5 states that the study  records should be retained unt il an am ount of time specified by  
applicable regulatory  requi rements or for a time specified in the Clinical Study  Site Agreement 
between the invest igator and sponsor.
Refer to the Clinical Study Site Agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive writt en approval fro m the sponsor before disposing of any 
such documents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 70of 105
Protocol Incorporating Amendment No. 3 02 October 2017
14.0 STATISTICAL METHODS
14.1 Statistical and Analytical Plans
A stati stical analysis plan (SAP) will be prepared and finalized prior to database lock. The SAP 
will provide further details regardin g the definit ion of analys is variables and analysis methodology 
to address all study  objectives.
14.1.1 Analysis Sets
Full analysis set: all rando mized patients. Patients will be analyzed according to the treatment 
assignment per the randomizat ion schedule. 
Safety analysis set: patients who receive at least 1 dose of study  drug. Pati ents will be analyzed 
according to the treatment actually received.
Response -evaluable analysis set: patients who receive at least 1 dose of study  drug, have 
measurable disease at Bas eline, and have 1 postbaseline disease assessment.
14.1.2 Analysis of Demographics and Other Baseline Characteristics
Dem ographic and baseline characterist ics (age, weight, height, and other parameters, as 
appropriate) will be summarized by  treatm ent arm . 
14.1.3 Effica cy Analysis
14.1.3.1 Primary Efficacy Endpoint
The primary endpo int is PFS, defined as the time from the date of rando mizat ion to the date of first 
docum entati on of  progressi on or death due to any  cause, whichever occurs first. For a patient 
whose disease has not p rogressed and is last known to be alive, or started alternate therapy prior to 
PD, PFS will be censored at the last response assessment that is SD or better. The primary efficac y 
analysis will be based on the full analysis set. 
The Kaplan -Meier m ethod wil l be used to analyze the distribut ion of PFS for each treatment arm. 
Kaplan -Meier survival curves, the 25th, 50th (median), and 75th percent iles, along wit h associated 
2-sided 95% confidence intervals (CIs), HR along with associated 95% CI, and Kaplan -Meie r 
estimates at relevant time po ints will be presented. The primary  hypothesis is to be tested at the 
0.10 significance level (2 -sided). The p -values from a stratified log -rank test and HRs and will be 
presented for each pair -wise comparison.
14.1.3.2 Secondary Efficacy Endpoints
Secondary  efficacy endpo ints include OS, ORR, TTP, CBR with SD of any durat ion, and CBR 
with SD durati on of  at least 6 m onths.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 71 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
OS is defined as the time from the date of randomization to the date of death. Patients without 
documentation of death at the time of  analysis will be censored at the date last known to be alive. 
OS will be analyzed using similar methods as the primary endpoint of PFS in the full analysis set.
ORR is defined as the proportion of patients who achieve a best response of CR or PR. CBR is 
defined as the proportion of patients who achieve a best response of CR, PR, or SD. The CBR will 
also be presented for a best response of CR, PR and SD of at least 6 months. A stratified 
Cochran-Mantel-Haenszel test will be used to compare ORR and CBR between treatment arms. 
The Mantel-Haenszel estimate of the odds ratio and the associated 95% CIs will be presented for 
each pair-wise comparison.
TTP is defined as the time from the date of randomization to the date of first documentation of
progression. For a patient whose disease has not progressed, TTP will be censored at the last 
response assessment that is SD or better. TTP will be analyzed using similar methods as the 
primary endpoint of PFS in the full analysis set.
14.1.4 PK Analysis
The sparse PK data are being collected to contri bute to a future population PK analysis. These data 
may be combined with data from other studies in which the PK of MLN0128 is characterized for 
population PK analy sis. The results of population PK analysis will be presented in a separate 
report.
14.1.5 Pharmacodynamic Analy ses/Biomarker Analyses
14.1.6 Patient-Reported Outcomes
Patient-reported outcome (PRO) assessments of HRQL using the EORTC QLQ-C30 and EORTC 
QLQ-BR23 questionnaires will be analyzed to determine if response to therapy and side effects of CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Useet..
R is is 
CBR wiCBR w
ed d 
atment atmen
be presbe pre
irst docst do
be censbe ce
ng similag simi
a future futur
hich thech th
PK anaPK an
AnalysAnaly
perty of Takeda: For Non-Commercial Use O
MLN0128 (TAK -228)
Study No. C31006 Page 72of 105
Protocol Incorporating Amendment No. 3 02 October 2017
therapy  are accom panied by measurable changes in the PROs. Published scoring manuals and 
guidelines will be used to generate scale scores and handle missing data.
Descript ive statistics for baseline values, actual values, and the change fro m Baseline will be 
presented at each scheduled time point for each of the funct ional and symptom scores fro m the 
EORTC QLQ -C30 and EORTC QLQ -BR23 quest ionnaires, and the global healt h status/QOL 
score from the EORTC QLQ -C30 questionnaire. All analyses will be based on the full analysis set. 
Differences between treatment arms in the EORTC QLQ -C30 and EORTC QLQ -BR23 scor es will 
be evaluated. Longitudinal analysis of PRO scores will be performed using linear mixed models.
14.1.7 Safety Analysis
Safety will be evaluated by  the incidence of AEs, severit y and t ype of AEs, and by changes fro m 
Baseline in the pat ient’s vit al signs, we ight, and clinical laboratory results using the safet y analys is 
set. Exposure to each study  drug (i e, MLN0128 and fulvestrant) will be summarized and reasons 
for discont inuat ion will be tabulated. Safety  will be summarized by  treatm ent arm .
TEAEs that occur after administration of the first dose of study drug and through 30 days after the 
last dose of study  drug will be tabulated. AEs will be tabulated according to the MedDRA 
dictionary and will  include the following categories:
TEAEs.
Drug -related TEAEs.
Grade 3 or higher TEAEs.
Grade 3 or higher drug- related TEAEs.
The m ost comm only reported TEAEs. 
SAEs.
A listing of AEs result ing in study  drug di scont inuation will be provided. A list ing of all deaths 
within 30 days after the last dose of study  drug will  also be provi ded.
Descript ive statistics for the actual values of clinical laboratory parameters (and/or change from 
Baseline in clinical laboratory  parameters) will be presented for all scheduled measurements over 
time. 
Shift tables for laboratory  parame ters will be generated based on changes in NCI CTCAE grade 
from Baseline to the worst postbaseline value.
Concomitant medicat ions will be coded using the WHO Drug Dict ionary. The number and 
percentage of patients taking conco mitant m edicat ions will be tabu lated by  WHO drug generi c 
term in the safety  analysis set.
ECG intervals (PR interval, QT interval, and QTc with Fridericia correction), QRS duration, and 
ventri cular rate will be summarized at each scheduled time point, along with mean change from 
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 73of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Baselin e to each post -treatm ent time point. The number and percentage of patients with ECG 
abnorm alities will be summarized at each time point.
14.2 Interim Analysis and Criteria for Early Termination
No formal interim analysis is planned. Details on considerations an d decisio n rules for early 
stopping for fut ility will be described in the SAP or a separate document.
14.3 Determination of Sample Size
The primary  efficacy  endpoint i s PFS. Assuming that the median PFS is 4 months for fulvestrant 
[36] and that the combination o f fulvestrant and MLN0128 (administered either QD or QW) can 
improve the median PFS to 8 months (HR of 0.5), then a total of 72 PFS events are needed for each 
pair-wise co mpar ison. Each treatment arm will require 51 patients. The calculat ions are based on a 
power of 90%, 2- sided alpha of 10%, and a dropout rate of 10% due to either lost to follow -up or 
withdrawal  of consent.
The accrual durat ion will be approxim ately  14 m onths. The final analysis for the pair- wise 
comparisons of PFS between fulvestrant+MLN0128 QD and fulvestrant, and between 
fulvestrant+MLN0128 QW and fulvestrant, is est imated to occur approximately 20 months after 
the first patient is rando mized .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 74of 105
Protocol Incorporating Amendment No. 3 02 October 2017
15.0 QUALITY CONTROL AND QUALITY ASSURANCE
15.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records. 
The invest igator and inst itution guarantee access to source documents by  the sponsor or i ts 
designee and by the IRB or IEC.
All aspects of the study and i ts docum entati on will be subject to review by the sponsor or designee 
(as long as blinding is not jeopardized), including but not limited to the Invest igator’s Binder, 
study  medicat ion, subject medical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and review o f eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are available during the mo nitoring visits and that sufficient time is 
devoted to the process.
15.2 Protocol Deviations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances aris e that will require 
deviat ion from protocol -specified procedures, the investigator should consult with the sponsor or 
designee (and IRB or IEC, as required) to determine the appropriate course of action. There will be 
no exempt ions (a prospectively approve d deviat ion) from the inclusio n or exclusio n criteria.
The site should document all protocol deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB or IEC, as 
requi red). Si gnificant devi ations include, but are not limited to, those that invo lve fraud or 
misconduct, increase the health risk to the subject, or confound interpretation of primary study 
assessment. A Protocol Deviat ion Form  or equivalent should be complet ed by  the si te and signed 
by the sponsor or designee for any  significant deviati on from the protocol.
15.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or desi gnees. In this 
circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected, 
where the medication is stored and prepared, and any other facilit y used during the study . In 
addition, there is the possibilit y that this study may be inspected by regulatory agencies, including 
those of foreign governments (eg, the FDA, the United Kingdo m Medicines and Healthcare 
products Regulatory  Agency , the Pharmaceut icals and Medical Devices Agency o f Japan). If the 
study  site is contacted for an inspect ion by a regulatory  body , the sponsor should be notified 
immediately . The invest igator and inst itution guarantee access for qualit y assurance auditors to all
study  docum ents as described in Section 15.1.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 75of 105
Protocol Incorporating Amendment No. 3 02 October 2017
16.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the eth ical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regulatory  requi rements and align his or her 
cond uct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The principles of Helsinki are addressed through the protocol and through appendices containing 
requi rements for info rmed consent and invest igator responsibilities.
16.1 IRB and/or IEC Approval
IRBs and IECs must be constituted according to the applicable state and federal/local requirements 
of each participat ing regio n. The sponsor or designee will require documentation noti ng all names 
and tit les of members who make up the respective IRB or IEC. If any member of the IRB or IEC 
has di rect parti cipat ion in this study , written notification regarding his or her abstinence fro m 
voting must also be obtained. Those American sites u nwilling to provide names and tit les of all 
members due to privacy  and conflict of interest concerns should instead provide a Federal Wide 
Assurance Number or comparable number assigned by the Department of Health and Human 
Services.
The sponsor or designe e will  supply relevant documents for submission to the respective IRB or 
IEC for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a copy o f 
the informed consent form, and, if applicable, subject recruit ment materials and/or a dvertisements 
and other documents required by all applicable laws and regulations, must be submitted to a 
central  or local IRB or IEC for approval. The IRB’s or IEC’s written approval of the protocol and 
subject informed consent must be obtained and submit ted to the sponsor or designee before 
commencement of the study  (ie, before shipment of the sponsor -supplied drug or study specific 
screening activit y). The IRB or IEC approval must refer to the study  by exact protocol tit le, 
number, and versio n date; iden tify versio ns of other documents (eg, informed consent form) 
reviewed; and state the approval date. The sponsor will notify the site once the sponsor has 
confirmed the adequacy of site regulatory  docum entati on and, when applicable, the sponsor has 
received permissio n from competent authorit y to begin the trial. Unt il the site receives notificat ion, 
no protocol act ivities, including Screening, may occur.
Sites m ust adhere to all requirements stipulated by  their respect ive IRB or IEC. This may include 
notific ation to the IRB or IEC regarding protocol amendments, updates to the informed consent 
form, recrui tment m aterials intended for viewing by  subjects, l ocal safety  reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at inter vals specified by the 
respective IRB or IEC, and submissio n of the investigator’s final status report to IRB or IEC. All 
IRB and IEC approvals and relevant documentation for these items must be provided to the 
sponsor or its designee.
Subject incentives sh ould not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB or IEC and sponsor.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 76of 105
Protocol Incorporating Amendment No. 3 02 October 2017
16.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent a s described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subject informat ion sheet (if applicabl e) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further expla in the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that she is free to withdraw at any time wit hout giving a reason and wit hout 
prejudice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB or IEC approval of the 
inform ed consent form  and if applicable, the subject authorization form. The informe d consent 
form, subject authorizat ion form (if applicable), and subject information sheet (if applicable) must 
be approved by both the IRB or IEC and the sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subje ct informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by the IRB or IEC. In the event the subject is not capable of renderi ng 
adequate written informed consent, then the subject’s legally  acceptable representative may 
provi de such consent for the subject in accordance with applicable laws and regulat ions.
The subject, or the subject’s legally acceptable representative, must be given ample opportunit y to: 
(1) inquire about details of the study and (2) decide whether or not to participate in the study. If the 
subject, or the subject’s legally acceptable representative, determines he or she will part icipate in 
the study , then the informed consent form and subject authorizat ion form (if applicable) m ust be 
signed and dated by  the subject, or the subject’s legally  acceptable representative, at the time of 
consent and prior to the subject entering into the study . The subject or the subject’s l egally 
acceptable representative should be instructed to sign using their legal names, not nicknames, 
using blue or black ballpo int ink. The invest igator must also sign and date the informed consent 
form and subject authorizat ion (if applicable) a t the time of consent and prior to subject entering 
into the study; however, the sponsor may  allow a designee of the invest igator to sign to the extent 
permitted by  applicable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed co nsent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 77of 105
Protocol Incorporating Amendment No. 3 02 October 2017
All revised informed consent forms must be reviewed and signed by relevant subjects or the 
relevant subject’s le gally  acceptable representative in the same manner as the original informed 
consent. The date the revised consent was ob tained shoul d be recorded in the subject’s medical 
record, and the subject should receive a copy  of the revised informed consent form.
16.3 Subject Confidentiality
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database o r documentation via a unique ident ificat ion number. As 
permitted by all applicable laws and regulat ions, limited subject attributes, such as sex, age, or date 
of birth, and subject init ials may be used to verify the subject and accuracy o f the subject’s un ique 
ident ificat ion number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the investigator to permit its monitor or designee’s monitor, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs and IECs to review the subject’s original medical records (source data or 
docum ents), including, but not limited to, laboratory test result reports, ECG reports, admissio n 
and discharge summaries for hospital admissio ns occurring during a subject’s study participation, 
and autopsy  reports. Access to a subject’s original medical records requires the specific 
authori zation of the subject as part of the informed consent process (see Section 16.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
16.4 Publication, Disclosure, and Clinical Trial Registration Policy
16.4.1 Publication and Disclosure
The investigator is obliged to provide the sponsor with comp lete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regul ation. Ex cept as otherwise allowable in the clinical study  site agreement, any  public 
disclosure (including publicly accessible websites) related to the protocol or study  resul ts, other 
than study  recrui tment m aterials and/or advertisements, is the sole responsibil ity of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will appropr iately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this secti on and the Clinical Study  Site Agreement. In the event of any discrepancy  between the 
protocol  and t he Clinical Study  Site Agreement, the Clinical Study  Site Agreement will prevail.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 78of 105
Protocol Incorporating Amendment No. 3 02 October 2017
16.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions and g uidance, Takeda will, at a minimum, register 
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing.
For some registries, Takeda will assist callers in lo cating trial sites closest to their ho mes by 
providing the invest igator’s name, address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encourag ed to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any invest igator who objects to Takeda providing this informat ion to callers must provide Takeda 
with a wri tten noti ce request ing that their informat ion not be listed on the registry site.
16.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov or other p ublicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
16.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the subj ect is parti cipat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to clinical study subjects. 
Refer to the Clinical Study  Site Agreement regarding the sponsor’s policy on subject 
compensat ion and treatment for injury. If the investigator has questions regarding this po licy, he or 
she should contact the sponsor or sponsor’s designee.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 79of 105
Protocol Incorporating Amendment No. 3 02 October 2017
17.0 REFERENCES
1.Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response 
evaluat ion criteria in solid tum ours: revi sed RECIST gui deline (versio n 1.1). Eur J Cancer 
2009;45(2):228 -47.
2.Siegel R, Nai shadham  D, Jemal  A. Cancer stati stics, 2013. CA Cancer J Clin 2013.
3.Malvezzi M, Bert uccio P, Levi F, La Vecchia C, Negri E. European cancer mortalit y 
predi ctions for the y ear 2013. Ann Onco l 2013;24(3):792 -800.
4.Ignat iadis M, Sotiriou C. Luminal breast cancer: from bio logy to treatm ent. Nat Rev Clin 
Onco l 2013.
5.Higgins MJ, Baselga J. Targeted therapies for breast cancer. J Clin Invest 
2011;121(10):3797 -803.
6.Guiu S, Mi chiels S, Andre F, Cortes J, Denkert C, Di Leo A, et al. Mo lecular subclasses of 
breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. Ann 
Oncol 2012;23(12):2997 -3006.
7.Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Mo lecular portraits 
of human breast tumours. Nature 2000;406(6797):747 -52.
8.Villarreal -Garza C, Cortes J, Andre F, Verma S. mTOR inhibitors in the manag ement of 
horm one receptor -posit ive breast cancer: the latest evidence and future directions. Ann Onco l 
2012.
9.Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expressio n patterns 
of breast carcino mas distinguish tumor subclasses with clinical  implicat ions. Proc Natl Acad 
Sci U S A 2001;98(19):10869-74.
10.Pritchard KI, Gelm on KA, Rayson D, Provencher L, Webster M, McLeod D, et al. Endocrine 
therapy  for postm enopausal  wom en wi th hormone receptor -positive her2 -negat ive advanced 
breast cancer after progression or recurrence on nonsteroidal aromatase inhibitor therapy : a 
Canadian consensus statement. Curr Oncol 2013;20(1):48 -61.
11.Dees EC, Carey LA. Improving endocrine therapy for breast cancer: it's not that simple. J Clin 
Onco l 2013;31(2):171 - 3.
12.Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, et al. The cyclin -dependent 
kinase 4/6 inhibitor palbociclib in co mbinat ion with letrozol e versus l etrozol e alone as 
first-line treatment of oestrogen receptor- positive, HER2 -negat ive, advanced breast cancer 
(PALOMA -1/TRIO -18): a randomised phase 2 study . Lancet Oncol  2015;16(1):25-35.
13.Pritchard KI. Endocrine therapy: is the first generatio n of targeted drugs the last? J Intern Med 
2013;274(2):144 -52.
14.Adelso n K, Germain D, Rapti s G, Bi ran N. Horm onal m odulati on in the treatm ent of breast 
cancer. Endocrino l Metab Clin North Am;40(3):519-32.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 80of 105
Protocol Incorporating Amendment No. 3 02 October 2017
15.Osborne CK, Schiff R. Mechanisms of endocrine resistance in breast cancer. Annu Rev Med 
2011;62:233 -47.
16.Jessen K, et al. INK1 28 Is a Potent and Select ive TORC1/2 Inhibitor With Broad Oral 
Antitumor Activit y. Mol  Cancer Therapy 2009;8(12):Abstract B148.
17.Kessler L, Wang S, Xin G, Kucharski J, Staunton J, Lan L, et al. INK128, an orally act ive 
TORC1/2 kinase inhibitor, shows br oad anti tumor activit y and enhances efficacy  of cytotoxi c 
as well as targeted agents. Cancer Res 2010;70(8; Supplement 1 Abstract 4496).
18.Hassan B, Akcakanat A, Takafumi S, Evans K, Adkins F, Meric -Bernstam  F. Inhibitor 
MLN0128 Has Ant itumor Efficacy In Cell Lines Wi th Intrinsic And Acquired 
Rapamycin -Resistance. Academic Surgical Congress 2013(Abstract ASC20130420).
19.Voss M, Gordon MS, Mita M, Rini B, Makker V, Macarulla T, et al. Phase I study  of 
investigat ional oral mTORC1/2 inhibitor TAK -228 (form erly MLN0128): expansio n phase in 
patients wi th renal, endo metrial, or bladder cancer. 2015.
20.Ghobrial IM, Siegel D, Vij R, Wolf JL, Berdeja JG, Matous JV, et al. MLN0128 (INK128), an 
Invest igational Oral Dual TORC1/2 Inhibitor, in Patients (pts) with R elapsed or Refractory  
Multiple Myelo ma (MM), Non -Hodgkin's Lymphoma (NHL), or Waldenstrom 
Macroglobulinemia (WM): Preliminary Results From a Phase 1 Dose -Escalation Study. ASH 
Annual Meet ing Abstracts 2012;120(21):4038.
21.Lonning PE. Addit ive endocrine t herapy for advanced breast cancer -back to the future. Acta 
Onco l 2009;48(8):1092 -101.
22.Bertelli G, Garrone O, Merlano M, Occelli M, Bertolotti L, Castiglio ne F, et al. Sequent ial 
treatm ent wi th exemestane and non -steroi dal aromatase inhibitors in adva nced breast cancer. 
Onco logy 2005;69(6):471 -7.
23.Van Tine BA, Crowder RJ, Ellis MJ. ER and PI3K independent ly modulate endocrine 
resistance in ER -positive breast cancer. Cancer Discovery  2011;1(4):287-8.
24.Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, et al. Double -blind, 
rando mized placebo con trolled tri al of fulvestrant com pared wi th exemestane after prior 
nonsteroidal aromatase inhibitor therapy  in postmenopausal wo men with horm one 
receptor -positive, advanced breast cancer: results fr om EFECT. J Clin Onco l 
2008;26(10):1664 -70.
25.Zagouri F, Sergentanis TN, Chry sikos D, Filipits M, Bartsch R. mTOR inhibitors in breast 
cancer: a sy stematic review. Gyneco l Onco l 2012;127(3):662 -72.
26.Miller TW, Hennessy  BT, Gonzal ez-Angulo AM, Fox EM, Mills GB, Chen H, et al. 
Hyperact ivation of phosphat idylinosito l-3 kinase prom otes escape from hormone dependence 
in estrogen receptor -posit ive human breast cancer. J Clin Invest 2010;120(7):2406 -13.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 81of 105
Protocol Incorporating Amendment No. 3 02 October 2017
27.Sanchez CG, Ma CX, Crowder RJ, Guintoli T, Phommaly C, Gao F, et al. Preclinical modeling 
of combined phosphat idylinosito l-3-kinase inhibit ion with endocrine therapy  for estrogen 
receptor -positive breast cancer. Breast Cancer Res 2011;13(2):R21.
28.Baselga J, Campone M, Piccart M, Burris HA, 3rd, Rugo HS, Sahmoud T, et al. Everolimus in 
postm enopausal horm one
-receptor -positive advanced breast cancer. N Engl J Med 
2012;366(6):520 -9.
29.Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, et al. Rando mized phase 
III placebo -controlled trial o f letrozole plus oral temsiro limus as first -line endocrine therapy in 
postm enopausal wom en wi th locally  advanced or metastati c breast cancer. J Clin Onco l 
2013;31(2):195 -202.
30.Massarweh S, Romond E, Black EP, Van Meter E, Shelton B, Kadamyan -Melkumian V, et a l. 
A phase II study  of combined fulvestrant and everolimus in pat ients with metastati c estrogen 
receptor (ER) -posit ive breast cancer after aromatase inhibitor (AI) failure. Breast Cancer Res 
Treat 2014;143(2):325 -32.
31.Boul ay A, Rudlo ff J, Ye J, Zumstein -Mecker S, O'Reilly T, Evans DB, et al. Dual inhibit ion of 
mTOR and estrogen receptor signaling in vitro induces cell death in models o f breast cancer. 
Clin Cancer Res 2005;11(14):5319 -28.
32.Commo n Termino logy Criteria for Adverse Events (CTCAE), Version 4.03. U.S. Department  
of Heal th and Human Services National Cancer Institute. 14 June 2010.
33.Wolff AC, Hammo nd ME, Hi cks DG, Dowsett M, McShane LM, Allison KH, et al. 
Reco mmendat ions for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer : 
American Societ y of Clinical  Oncol ogy/College o f American Pathologists Clinical Practice 
Guideline Update. Arch Pathol Lab Med 2013.
34.Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European 
Organizat ion for Research and T reatment of Cancer QLQ -C30: a qualit y-of-life instrument for 
use in internat ional clinical trials in onco logy. J Natl  Cancer Inst 1993;85(5):365-76.
35.Nguy en J, Popovic M, Chow E, Cella D, Beaumont JL, Chu D, et al. EORTC QLQ -BR23 and 
FACT -B for the assessment of qualit y of life in patients with breast cancer: a literature review. 
J Com p Eff Res 2015;4(2):157-66.
36.Turner NC, Ro J, Andre F, Lo i S, Verm a S, Iwata H, et al . Palboci clib in 
Horm one-Receptor -Positive Advanced Breast Cancer. N Engl J Med 2015 ;373(3):209-19.
37.Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicit y and 
response criteria of the Eastern Cooperative Onco logy Group. Am  J Clin Oncol  
1982;5(6):649 -55.
38.Cockcroft DW, Gault MH. Prediction of creat inine clea rance fro m serum  creat inine. Nephron 
1976;16(1):31 -41.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 82of 105
Protocol Incorporating Amendment No. 3 02 October 2017
39.The Cri teria Co mmit tee of  New York Heart Associat ion. Nom enclature and Criteria for 
Diagnosis of Diseases of the Heart and Great Vessels. 9 ed. Boston, MA: Little, Brown & Co; 
1994.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 83of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix ASchedule of Events
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 84of 105
Protocol Incorporatin g Amendment No. 3 02 October 2017
Schedule of Events
Screening (a)TreatmentPC 
EOT 
(b)EOT 
(c)PFS/OS 
Follow -up Cycle 1 Cycle 2 Cycle 3 Cycle 4Cycle 5 and 
Beyond
D -28 to D -1 D1 D15 D1 D15 D1 D1 D1
Informed consent X X
Inclusion/exclusion criteria X X
Demographics X
Medical history X
Height X
Weight X X X X X X X X
Physical examination X X X X X X X X X X
Vital signs (d) X X X X X X X X X X
ECOG performance status X X X X X X X X
12-lead ECG (single) (e) X X X X X X X X
Radiographic tumor evaluation (f) X Every other cycle, starting with Cycle 2 (f) X X X (g)
Bone scan (h) X As necessary to monitor representative areas, at the investigator’s discretion.
Subs equent cancer therapy X X (g)
Follow -up pho ne calls (OS) X (g)
HRQL assessments (i) X X X X X X
Monitoring of concomitant 
medications and proceduresRecorded from first dose of study drug through 30 days after the last dose of s tudy 
drug
AE reporting Recorded from first dose of study drug through 30 days after the last dose of 
study drug
SAEs (j) will be reported from signing of the informed consent form through 30 days after the last 
dose of study drug.
Footnotes are on last table page.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 85 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Schedule of Events (continued)
Screening (a)TreatmentPC 
EOT 
(b)EOT 
(c)PFS/OS 
Follow-up Cycle 1 Cycle 2 Cycle 3 Cycle 4Cycle 5 and 
Beyond
D -28 to D -1 D1 D15 D1 D15 D1 D1 D1
MLN0128 administration (Combination arms only) (k)According to treatment arm assignment: daily (Arm B)
or weekly (Arm C; ie, Days 1, 8, 15, and 22 of each 28-day cycle)
Fulvestrant administration 
(All treatment arms) (k)Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 1,
and then once every 4 weeks
Patient dosing diary instructions/reviewXX X X X X
Samples/Laboratory Assessments
Hematology and chemistry (l) X X X X X X X X X X
Coagulation (PT/INR, aPTT) X X X X X X X X
Fasting lipid profile X X X X X X X
HbA1c X X Q3C (m) X
Urinalysis (l) X (n) X (n)
Fasting serum glucose (o) X X X X X
In-home FBG monitoring (p) For patients in Arms B and C, daily from Cycle 1 Day 2 through last dose 
of study drug (may be decreased to once a week after the first 2 months, as 
detailed in Section 10.4.15) . In-home glucose monitoring is not required 
on days when fasting glucose is measured in the clinic.
Footnotes are on last table page.CCI
CCI
Property of TaTapage.page.Non-Commercial Use Only and Subject to the Applicable Terms of UseTe
ca
4CycleCyc
Bpl
A
D1D1he
nt: daily : dai
22 of ea22 of eot
yy 15, Cyc15, Cyy
every 4every 4 wwec
XXSu
ndannn
XXnlyOXOOOe OXXUsee
llllUalciaaa
mmmmemm For patieor pati
of studof stu
detmmmmmm
n
N
For N:F:F
Takeda: 
MLN0128 (TAK-228)
Study No. C31006 Page 86 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Schedule of Events (continued)
Screening (a)TreatmentPC 
EOT 
(b)EOT 
(c)PFS/OS 
Follow-up Cycle 1 Cycle 2 Cycle 3 Cycle 4Cycle 5 and 
Beyond
D -28 to D -1 D1 D15 D1 D15 D1 D1 D1
Blood sample for plasma PK (t) X X X
AE=adverse event, aPTT=activated partial thromboplastin time, CT=computed tomography, CTC=circulating tumor cell, ctDNA=circula ting tumor DNA, D=day, 
DNA=deoxyribonucleic acid, ECG=electrocardiogram, ECOG=Eastern Cooperative Oncology Group, EOT=End-of-Treatment visit, FBG=fast ing blood glucose, 
HbA1c=glycosylated hemoglobin, HRQL=health-related quality of life, INR=international normalized ratio, MRI=magnetic resonance scan, OS=overall survival, 
PC EOT=Precrossover End-of-Treatment visit, PT=prothrombin time, PFS=progression-free survival, PK=pharmacokinetic(s), PTE=pret reatment event, 
SAE=serious adverse event.
Tests and procedures should be performed on schedule, but occasional changes are allowable (±2 days) for holidays, vacations, an d other administrative reasons, 
starting after the completion of Cycle 2 Day 1. (a) Screening assessments are performed w ithin 28 days before administration of the first dose of study drug. Screening assessm ents performed no m ore than 3 days 
before the first dose will qualify as baseline (Cycle 1 Day 1) assessments and need not be repeated, unless otherwise specified .
(b) Patients randomized to the single-agent fulvestrant arm who progress on study may be eligible for crossover treatment. It is recommended that crossover 
treatment begin within 28 days (+10 days) after documented disease progression (imaging date of PD), with the goal of maintaining  the ongoing schedule of 
fulvestrant therapy (ie, dosing every 28 days). Whenever possible, MLN0128 should be initiated at the next scheduled dose of fu lvestrant, but only when the patient 
has completed the precrossover screening requirements and is eligible to continue. If the crossover treatment cannot begin with in 28 days (+10 days) after 
documented PD, contact the medical monitor.CCICCI
Property of Takeda: For Non-Commercial Use Only and SuSu
ndndndnd graphy, Caphy
ve Oncove Onc
nternationnternatio
progressogres
changeschange
dministraministr
ssessmensessme
who prowho pr
nted diseted dis
ver possier pos
ments andents anececececthe Applicable Terms of UseTe
ca
4CycleCyc
Bpl
A
D1D1he
Subjecect to th
MLN0128 (TAK -228)
Study No. C31006 Page 87of 105
Protocol Incorporatin g Amendment No. 3 02 October 2017
(c) Patients will attend an EOT Visit 30 to 40 days after receiving their last dose of study drug, or at the start of subsequent anticancer therapy (incl uding crossover 
treatment as described in Section 7.1), at which time patients will e nter posttreatment follow -up. If subsequent anticancer therapy is required before 30 days after the 
last dose, the EOT Visit should be conducted before the initiation of subsequent anticancer therapy.
(d) Perform vital signs measurement prior to study drug administration. Vital sign measurements include blood pressure (diastolic and systolic), heart rate, and 
temperature.
(e) A single, 12 -lead ECG will be performed predose on Day 1 of ever y cycle, and during the EOT Visit. When the timing of an ECG coincide s with blood samples, 
the ECG should be completed first. Additional ECGs may be obtained as clinically indicated.
(f) Baseline CT scan (with contrast) or MRI of the chest, abdomen, and pelvis must be obtained within 21 days before the firs t dose of study d rug. Starting at 
Cycle2, CT scan (with contrast) or MRI will be performed at the end of every other cycle, within 7 days before Day 1 of the next c ycle; for example, the Cycle 2 
evaluation must be done within 7 days before Cycle 3 Day 1, the Cycle 4 evalu ation must be done within 7 days before Cycle 5 Day 1, etc. For those patients who 
have documented radiographic PD, CT scan (with contrast) or MRI are not required at the EOT Visit. The same imaging modality (CT scan [with contrast] or MRI) 
will be used th roughout the study.
(g) Patients who discontinue study treatment for reasons other than PD will continue to have PFS follow -up visits ever y 2 months (±1 week) for the first 6 months 
after the EOT Visit and then every 3 months (±1 week), until PD or start o f another anticancer therapy, whichever occurs first. After PD or start of another 
anticancer therapy (including crossover treatment as described in Section 7.1)
, all patients will be followed only for survival every 6 months (±1 week) .
(h) A bone scan will be required for all patients within 21 days before the first dose of study drug), and thereafter at the discretion of the investigator to monitor 
representative areas.
(i) HRQL instruments to be used are the E ORTC QLQ -C30 and the EORTC QLQ -BR23, and must be completed before other assessments are performed or study 
drug is administered.
(j) Including serious PTEs; see Section 11.0.
(k) The first dose of study drug mus t be administered within 5 days after randomization on study. In Arm B, daily MLN0128 will be administered on an empty 
stomach; in Arm C, weekly MLN0128 will be administered with a light meal (see Section 9.1).
(l) Refer to Section 10.4.14 for a list of the required clinical laboratory assessments. Laboratory assessments may be performed within 24 hours before th e required 
study visit. Safety laboratory results must be available and reviewed by the investigator before study drug administration. Electrolyte levels should be corrected as 
needed before study drug administration. Preassessment fasting is not required for on Cycle 1 Day 15 or Cycle 2 Day 15.
(m) Starting at Cycle 6, HbA1c and urinalysis will be assessed ever y 3 cycles (Cycle 6, Cycle 9, Cycle 12, etc).
(n) For Screening, creatinine clearance must be ≥40 mL/min based either on Cockroft -Gault estimate or based on a 12- or 24 -hour urine collection.
(o) Fasting s erum glucose will be measured in the clinic. Patients are required to fast overnight (nothing except water and/or medications after midnight or for a 
minimum of 8 hours before the assessment) for each of these measurements. For patients receiving single -agent fulvestrant in Arm A or fulvestrant+MLN0128 QW 
in Arm C, the fasting serum glucose may be assessed as part of the predose chemistry panel. After fasted sampling is complete , patients receiving 
fulvestrant+MLN0128 QW in Arm C should consume a light meal prior to dosing (Section 9.1). For patients receiving fulvestrant+MLN0128 QD in Arm B, a 
separate sample must be taken approximately 2 hours after study drug administration, with patients continuing to fast unt il that sample is taken. The collection of the 
2-hour postdose sample is not expected on the nondosing days. In-home glucose monitoring is not required on days when fasting glucose is measured in the clinic.
(p) Patients in the combination fulvestrant+MLN0 128 treatment arms (Arm B and Arm C) will be given a glucometer to monitor daily fasting glucose levels at 
home and will be instructed to notify the study clinician any time the fasting glucose is abnormal (ie, ≥150 mg/dL). See Section
 10.4.15 for further instructions.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK-228)
Study No. C31006 Page 88 of 105
Protocol Incorporating Amendment No. 3 02 October 2017
(q) .
(r) (s)  
 
 
(t) PK samples will be collected only from patients receiving MLN0128, including patients receiving crossover treatment, but no t from patients randomized to 
single-agent fulvestrant. Samples will be collected at the times specified in the  Treatment Arm B Sparse PK Sample Breakdown and Treatment Arm C Sparse PK
Sample Breakdown.  For all PK samples, the date and time of MLN0128 dosing and the date and time of PK sampling will need to be recorded.CCI
CCICCI
Property of Takeda: For Non-Commercial Use Only and Subject to thecrossoverosso
parse PKrse PK
d time of ime oplica
AppliApp
the ATerms of UseTe
able Teicab
MLN0128 (TAK -228)
Study No. C31006 Page 89of 105
Protocol Incorporatin g Amendment No. 3 02 October 2017
Treatment Arm B Sparse PK Sam ple Breakdown
MLN0128 Sparse PK Sampling (Plasma)
Cycle 1 Day 1 (a) Cycle 1 Day 15 (b) Cycle 2 Day 1 (c)
At time of clinic visit (anytime postdose) X1 X1
Approximately 1 hour after prior PK sample collection X1 X1
1 to 2 hours postdose (±15 min) X1
PK=pharmacokinetic(s), X#=the number of samples required (eg, 2 samples=X2).
This PK sampling schedule applies to subjects initially randomized to Arm B and those receiving crossover treatment in Arm B.
(a) The exact date and time of MLN0128 dosing o n Cycle 1 Day 1 and the date/time of PK sampling must be recorded. Over the course of the study, a distribution 
of sampling times within the specified sampling windows is encouraged.
(b) On Cycle 1 Day 15, subjects will take their regularly scheduled doses of MLN0128 at home and will record the exact date/time of dose administration in their 
subject diaries. Subjects will then report to the clinic for the scheduled visit, during which they will provide PK samples. Over the course of the study, a distributio n 
of clinic visit/sampling times (eg, morning through late afternoon) for this visit is encouraged.
(c) On Cy cle 2 Day  1, subjects will take their regularly scheduled doses of MLN0128 in the clinic after completion of fasting serum glucose sampling. The ex act 
date/time of dose administration and the date/time of PK sampling must be recorded. Over the course of the study, a distribut ion of clinic visit/sampling times (eg, 
morning through late afternoon) for this visit is encouraged.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 90of 105
Protocol Incorporatin g Amendment No. 3 02 October 2017
Treatment Arm C Sparse PK Sample Breakdown
MLN0128 Sparse PK Sampling (Plasma)
Cycle 1 Day 1 (a) Cycle 1 Day 15 (b) Cycle 2 Day 1 (c)
At time of clinic visit (anytime postdose) X1 X1
Approximately 1 hour after prior PK sample collection X1 X1
1 to 2 hours postdose (±15 m in) X1
3 to 6 hours postdose (±30 min) X2 (d)
PK=pharmacokinetic(s), X#=the number of samples required (eg, 2 samples=X2).
This PK sampling schedule applies to subjects initially randomized to Arm C and those receiving crossover treatment in Arm C.
(a) Subjects should bring a light meal with them to this visit. Subjects will begin consuming the meal within 30 min prior to dosing, after which they will take their 
doses of MLN0128. The exact date/time of meal consumption, MLN0128 dosing, and PK sampling must be recorded. Over the course of the study, a distribution of 
sampling times within the specified sampling windows is encouraged.
(b) Subjects will take their regularly scheduled doses of MLN0128 at home with a light meal and will record the exact dat e/time of meal consumption and dose 
administration in their subject diaries. Subjects will then report to the clinic for the scheduled visit, during which they w ill provide PK samples. The date/time of PK 
sampling must be recorded. Over the course of the s tudy, a distributio n of clinic visit/sampling times (eg, morning through late afternoon) for this visit is 
encouraged.
(c) Subjects should bring a light meal with them to this visit. After completion of fasting serum glucose sampling, subjects will begin c onsuming the meal within 
30min prio r to dosing, after which they will take their regularly scheduled doses of MLN0128. The exact date/time of meal consu mption, MLN0128 dosing, and 
PK sampling must be recorded. Over the course of the study, a distribution of clinic visit/sampling times (eg, morning through late afternoon) for this visit is 
encouraged.
(d) Two samples will be taken no less than 1 hour apart within the specified window.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 91of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix BResponsibilities of the Invest igator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which must be completed and 
signed before the invest igator may participate in this study .
The invest igator agrees to assume the fo llowing responsibilit ies by signing Form FDA 1572:
Conduct the study  in accordance wit h the protocol.
Personally conduct or supervise the staff who will assist in the protocol.
Ensure that study -related procedures, including study  specific (nonroutine/nonstandard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authorit ies.
Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
Secure prior approval o f the study and any changes by an appropriate IRB/IEC that conform to 
21 CFR Part 56, ICH, and local regulatory requirements.
Ensure that the IRB/IEC will be responsible for init ial review, continuing review, and approva l 
of the protocol. Promptly report to the IRB/IEC all changes in research act ivity and all 
anticipated risks to subjec ts. Make at l east y early reports on the progress of the study  to the 
IRB/IEC, and issue a final report within 3 months of study  com pletion.
Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH, and local 
regul ations, are m et.
Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB/IEC. Each informed consent form should con tain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal healt
h informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include such a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject or the 
subject’s legally acceptable representative.
Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc., and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and receive written approval fro m the sponsor before disposing o f any such 
docum ents.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 92of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
Maintain current records of t he receipt, administratio n, and disposit ion of sponsor -supplied 
drugs, and return all unused sponsor -supplied drugs to the sponsor.
Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
If the invest igator/institution retains the services of any individual or party to perform 
trial-related duti es and funct ions, the invest igator/inst itution shoul d ensure that this individual 
or party  is qualified to perform those trial -related duti es and funct ions and shoul d implement 
procedures to ensure the integrit y of the tri al-related duti es and funct ions performed and any 
data generated.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 93of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix CInvestigator Consent to Use of Personal Information 
Takeda will collect and retain pe rsonal  information of  invest igator, including his or her name, 
address, and other personally identifiable informat ion. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom , Uni ted States, and Japan), including the following:
Takeda, its affiliates, and licensing partners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs and IECs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, m onitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical co mpound present in the study medicat ion.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting invest igator site contact informat ion, study details, and results on publicly accessible 
clinical trial registries, databases, and websites.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws tha t offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and consents to the use of his or her personal information by Takeda 
and other parties for the purposes described above.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 94of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix DECOG Scale for Performance Status
Grade Description
0 Normal activity. Fully active, able to carry on all predisease performance without restriction.
1 Symptoms but ambulatory. Restricted in physically strenuous activity, but amb ulatory  and able to 
carry  out work of a light or sedentary nature (eg, light housework, office work).
2 In bed <50% of the time. Ambulatory and capable of all self -care, but unable to carry out any work 
activities. Up and about more than 50% of waking hou rs.
3 In bed >50% of the time. Capable of only limited self -care, confined to bed or chair more than 50% of 
waking hours.
4 100% bedridden. Completely disabled. Cannot carry on any self -care. Totally confined to bed or 
chair.
5 Dead
ECOG=Eastern Cooper ative Oncology Group.
Source: Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria 
of the Eastern Cooperative Oncology Group. American Journal of Clinical Oncology 1982;5(6):649 -55 [37].
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 95of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix ECockcroft -Gault Equation
For wom en:
Creatinine Clearance = 0.85 (140 -age [y ears]) weight [kg]
72(serum creat inine [mg/dL])
OR
Creatinine Clearance = 0.85 (140-age [y ears]) weight [kg]
0.81(serum creatinine [µmo l/L])
Source: Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 
1976;16(1):31 -41. [38]
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 96of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix FNew York Heart Association Classification of Cardiac Disease
Class Functional Capacity Objective Assessment
I Patients with cardiac disease but without resulting limitations of 
physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnea, or anginal pain.No objective evidence of 
cardiovascular disease.
II Patients with cardiac disease resulting in slight limitation of physical 
activity . They  are comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnea, or anginal pain.Objective evidence of minimal 
cardiovascular disease.
III Patients with cardiac disease resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary 
activity  causes fatigue, palpitation, dyspnea, or a nginal pain.Objective evidence of moderately 
severe cardiovascular disease.
IV Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort. Symptoms of heart failure or 
the anginal syndrome may be present eve n at rest. If any physical 
activity  is undertaken, discomfort is increased.Objective evidence of severe 
cardiovascular disease.
Source: The Criteria Committee of New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases 
of the Heart and Great Vessels. Ninth Ed. Boston, MA: Little, Brown & Co; 1994:253 -256. [39]
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 97of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix GList o f Relevant Cytochrome P450 Inhibitors and Inducers
Moderate CYP1A2 Inhibitors
Cimetidine Methoxsalen 
Strong CYP1A2 Inhibitors
Fluvoxamine Ciprofloxacin
Clinically Significant Enzyme Inducers
Carbamazepine Rifabutin St. Jo hn’s Wort
Phenobarbital Rifampin Phenytoin
T=Rifapentine 
Source: fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/DrugInteractionsLabeling/ 
ucm093664.htm.
Note that these lists are not exhaustive.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 98of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix HEORTC QLQ -C30 Version 3
:Please go on to the next page
EORTC QLQ- C30 (version 3)
We are interested in some things about you and your health. Plea se answer all of the questions
yourself by circling the number that best applies to you. There are no "right" or "wrong"
answers. The information that you provide will remain strictly c onfidential.
Please fill in your initials:
Your birthdate (Day, Month, Year):
Today's date (Day, Month, Year): 
Not at A Quite Very
all little a bit much
1.Do you have any trouble doing strenuous activities,
like carrying a heavy shopping bag or a suitcase? 1 2 3 4
2.Do you have any trouble taking a long walk? 1 2 3 4
3.Do you have any trouble taking a short walk outside
of the house? 1 2 3 4
4.Do you need to stay in bed or a chair during the day? 1 2 3 4
5.Do you need help with eating, dressing, washing
yourself or using the toilet? 1 2 3 4
During the past week: Not at A Quite Very
All little a bit much
6.Were you limited in doing either your work or other
daily activities? 1 2 3 4
7.Were you limited in pursuing your hobbies or other
leisure time activities? 1 2 3 4
8.Were you short of breath? 1 2 3 4
9.Have you had pain? 1 2 3 4
10.Did you need to rest? 1 2 3 4
11.Have you had trouble sleeping? 1 2 3 4
12.Have you felt weak? 1 2 3 4
13.Have you lacked appetite? 1 2 3 4
14.Have you felt nauseated? 1 2 3 4
15.Have you vomited? 1 2 3 4
16.Have you been constipated? 1 2 3 4
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 99of 105
Protocol Incorporating Amendment No. 3 02 October 2017
©Copyright 1995 E ORTC Q uality of Life S tudy Group.  All rights  reserved.  Vers ion 3.0During the past wee k: Not at A QuiteVery
all little a bit much
17.Have you ha d dia rrhea ? 1 2 3 4
18.Were you ti red? 1 2 3 4
19.Did pa in inte rfere w ith your da ily activities? 1 2 3 4
20.Have you ha d difficulty in concentra ting on things ,
like reading a new spaper or w atching tel evision? 1 2 3 4
21.Did you fe el tense? 1 2 3 4
22.Did you w orry? 1 2 3 4
23.Did you fe el irrita ble? 1 2 3 4
24.Did you fe el depres sed? 1 2 3 4
25.Have you ha d difficulty remembe ring things ? 1 2 3 4
26.Has your phys ical condition or medica l trea tment
interfered w ith your family life? 1 2 3 4
27.Has your phys ical condition or medica l trea tment
interfered w ith your social activities? 1 2 3 4
28.Has your phys ical condition or medica l trea tment
caused you fina ncial difficultie s? 1 2 3 4
For the following  ques tions  pleas e circle the number betw een 1 and 7 that
best applies  to you
29.How would you ra te your overa ll health during  the past week?
1 2 3 4 5 6 7
 Very poor          E xcellent
30.How would you ra te your overa ll quality of life  during the pa st week?
1 2 3 4 5 6 7
 Very poor          E xcellent
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 100of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix IEORTC QLQ -BR23
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 101of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 102of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Appendix JDetailed Description of Amendments to Text
The primary  secti ons of the protocol affected by  the changes in Amendment No. 3 are indicated. 
The cor responding text has been revised throughout the protocol.
Chan ge 1: Remove the exclusio n criterion rel ating to treatment with strong CYP inhibitors or 
inducers.
The pr imary change occurs in Secti on8.2Exclusio n Cri teria:
Deleted text: 11. Treatment with strong cytochrome P450 (CYP) 3A4, CYP2C9, and/or CYP2C19
inhibitors and/or induc ers wi thin 1 week before the first dose of study  drug (see 
Appendix G ).
Rationale for Change:
This change, which removes enrollment restrict ions for pati ents taking CYP3A4, CYP2C9, or 
CYP2C19 inhibitors and/or inducers in this study , was m ade due to updat ed data on MLN0128 
metabo lism by specific CYP iso forms.
Change 2: Update the list of concomitant medications prohibited during the study.
The primary  change occurs in Secti on 9.5.2 Excluded Concomitant Medicat ions and Procedures 
for Combinat ion MLN0128 Plus Fulvestrant Treatment Arms (Arm B and Arm C) :
Initial 
wording:Strong CYP3A4 and CYP2C19 inducers and/or inhibitors and moderate 
inhibitors of CYP2C9 (see Appendix G) shoul d be administer ed only with 
cauti on and at the discret ion of the invest igator. Alternative trea tments, if 
available, should be consi dered.
…
[…] Examples of histamine H2 receptor antagonists include ranit idine, 
famotidine, nizat idine, and c imetidine.
Amended or 
new 
wording:Strong CYP3A4 and CYP2C19 inducers and/or cytochrome P450 (CYP) 1A2 
inhibitors and CYP inducers shoul d be administ ered with caut ionand at the 
discreti on of  the invest igator (see Appendix Gfor a list of these agents) .
Alternat ive treatments, if available, should be considered. (Refer to Appendix G
for a list of strong inhibit ors and strong inducers of CYP2C9, CYP2C19, and 
CYP3A4.)
…
[…] Examples of histamine H2 receptor antagonists include ranit idine, 
famotidine, and nizat idine, and c . Cimetidine, a moderate CYP1A2 inhibitor, 
is not recommended as a first choice H2 receptor ant agonist (see Appendix 
G).
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 103of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Rationale for Change:
This change was made to update the recommendat ions on concomicant medicat ion use during the 
study  based on updated data on MLN0128 metabo lism by specific CYP iso forms.
Change 3: Update the list of relevant CYP inhibit ors and inducers.
The primary  change occurs in Appendix GList o f Relevant Cy tochrom e P450 Inhibi tors and 
Inducers :
Descript ion 
of the 
change:The list of relevant CYP inhibitors and induce rs was updated to remove sections 
listing strong CYP2C19 inhibitors and strong and moderate CYP3A4 inhibito rs,to 
add asection listingstrong and moderate CYP1A2 inhibitors ,and to update t he 
section listing clinically significant enzyme inducers .
Rationale for Change:
This change was made for consistency wit h updated data on MLN0128 metabo lism by specific 
CYP isoforms.
Change 4: Remove dietary  restri ctions related to CYP i nhibitors and inducers.
The primary  change occurs in Section 9.5.2 Excluded Concomitant Medicat ions and Procedures 
for Combinat ion MLN0128 Plus Fulvestrant Treatment Arms (Arm B and Arm C) :
Deleted text: In addit ion to the above medicat ions, consumpt ion of grapefruit o r grapefruit juice is 
not permitted during the study . Pati ents shoul d not consume food or beverages 
containing the fruit or juice of grapefruit s or Seville oranges within 7 days before the 
first dose of study  drug and throughout the study  (see Appendix G) 
Rationale for Change:
This change was made for consistency wit h new data that removes the necessit y for restri ctions 
concerning CYP2C9 and 2C19.
The fo llowing sect ions also contain this change:
Secti on 9.7Precautions and Restrict ions.
Appendix GList o f Relevant Cy tochrom e P450 Inhibitors and Inducers .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 104of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Change 5: Update thenumber of study  sites.
The primary  change occurs in Secti on 7.2Number of Patients :
Initial 
wording:Approximately  153 pati ents (51 pati ents per treatment arm) will be enrolled in this 
study  from approximately 55 study centers in North America and Europe. A patient is 
considered to be enrolled in the study when she has been randomized into a tr eatment 
arm.
Amended or 
new 
wording:Approximately  153 pati ents (51 pati ents per treatment arm) will be enrolled in this 
study  from approximately 55 65study  centers in North America and Europe. A 
patient is considered to be enrolled in the study when she has been rando mized into a 
treatm ent arm .
Rationale for Change:
This change was made to ensure that enrollment was achieved within the timelines.
Secti on 2.0STUDY SUMMARY also contains this change.
Change 6: Update the recommendat ions for init iation of crossover treatment.
The primary  change occurs in Section 7.1.4 Potential for Crossover Treatment :
Initial 
wording :Crossover treatment must begin wit hin 28 days after documented PD. The ongoing 
schedule of fulvestrant therapy  shoul d be maintaine d (ie, dosing every  28 days), and 
MLN0128 should be init iated at the next scheduled dose of fulvestrant. This will  be 
Cycle 1 Day  1 of the crossover treatment.
Amended or 
new 
wording:It is recommend edthat Ccrossover treatment mustbegin within 28 days ( +10 days) 
days after documented disease progression (imaging date of PD), with the goal of 
maintaining Ttheongoing schedule of fulvestrant therapy  shoul d be maintained (ie, 
dosing every 28 days) , and .Whenever possible, MLN0128 should be init iated at the 
next scheduled dose of fulvestrant ,but only when the patient has completed the 
precrossover screening requirements and is eligible to continue. If the crossove r 
treatment cannot begin within 28 days ( +10 days) after documen ted PD, contact 
the medical moni tor.This will be Cycle 1 Day  1 of the crossover treatment.
Rationale for Change:
This change was made to reflect updated dosing recommendat ions.
Appendix ASchedule o f Events also contains this change.
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
MLN0128 (TAK -228)
Study No. C31006 Page 105of 105
Protocol Incorporating Amendment No. 3 02 October 2017
Change 7: Update guidance for fasting serum glucose post-dose collection on non -dosing days.
The primary  change occurs in Appendix ASchedule of Events :
Descript ion 
of the 
changeA sentence was added to footnote (o)to clarify  that collecti on of  the 2 hour post -dose 
sample i s not expected on non -dosing day s.
Rationale for Change:
This change was made to increase the ease and accuracy  of recording data at the site level.
The fo llowing sec tions also contain this change:
Appendix ASchedule o f Events .
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of Use
䢢
䢢䢢䢢
䢢
䢢䢢
䢢
(/(&7521,& 6,*1$785(6 
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 

  

  

  

   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


   


GG䣃䣰䢢䣑䣲䣧䣰䢯䣎䣣䣤䣧䣮䢢䣒䣪䣣䣵䣧䢢䢴䢢䣕䣶䣷䣦䣻䢢䣱䣨䢢䣏䣎䣐䢲䢳䢴䢺䢢䢪䣃䢢䣖䣑䣔䣅䢳䢱䢴䢢䣋䣰䣪䣫䣤䣫䣶䣱䣴䢫䢢䣫䣰 䢢䣅䣱䣯䣤䣫䣰䣣䣶䣫䣱䣰䢢䣙䣫䣶䣪䢢䣈䣷䣮䣸䣧䣵䣶䣴䣣䣰䣶䢢䣫䣰䢢䣙䣱䣯䣧䣰
䣙䣫䣶䣪䢢䣇䣔䢯䣒䣱䣵䣫䣶䣫䣸䣧䢱䣊䣇䣔䢴䢯䣐䣧䣩䣣䣶䣫䣸䣧䢢䣃䣦䣸䣣䣰䣥䣧䣦䢢䣱䣴䢢䣏䣧䣶䣣䣵䣶䣣䣶䣫䣥䢢䣄䣴䣧䣣䣵䣶䢢䣅䣣 䣰䣥䣧䣴䢢䣖䣪䣣䣶䢢䣊䣣䣵䢢䣒䣴䣱䣩䣴䣧䣵䣵䣧䣦䢢䣆䣷䣴䣫䣰䣩䢢䣱䣴䢢䣃䣨䣶䣧䣴
䣃䣴䣱䣯䣣䣶䣣䣵䣧䢢䣋䣰䣪䣫䣤䣫䣶䣱䣴䢢䣖䣪䣧䣴䣣䣲䣻
&OLQLFDO3KDUPDFRORJ\$SSURYDO 2FW87&
%LRVWDWLVWLFV$SSURYDO 2FW87&
&OLQLFDO$SSURYDO 2FW87&PPD
Property of Takeda: For Non-Commercial Use Only and Subject to the Applicable Terms of UseeT eate te
ble THH:mm ‘UH:mmTer
ble87&87&

2FWFW